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Résumé 
 
L’anémie falciforme est l’une des maladies du sang les plus répandues chez l’homme. Les 
complications liées à la maladie sont systémiques. Influant virtuellement tous les organes du corps, 
cette affection provoque des crises de douleurs imprévisibles et aigües dont les complications mènent 
parfois à la mort. Le processus à travers lequel un globule rouge sain prend la forme d’une faucille est 
bien décrit dans la littérature; sous désoxygénation, l’eau et les solutés se retirent des globules rouges, 
la concentration d’hémoglobine S augmente et nous donne des globules rouges denses et déshydratés 
qui par la suite deviennent falciformes. Les traitements d’aujourd’hui sont pour la plupart 
expérimentaux et coûteux. De plus, leurs efficacités à long terme varient d’un patient à l’autre. Il est 
donc impératif de trouver un biomarqueur qui est à la fois abordable et qui améliore la santé des 
malades de façon systématique. La densité des globules rouges est un biomarqueur largement ignoré 
par la communauté médicale dans le contexte de la drépanocytose. Aborder l’étude de la sévérité de 
cette maladie en se concentrant sur la densité des globules rouges nous met en position d’identifier des 
traitements pour réhydrater les érythrocytes et leur rendre leur forme originale de disque biconcave. 
Plusieurs études cliniques et physiologiques se sont penchées sur ce biomarqueur sans explorer le volet 
génétique. Nous avons cherché à éclaircir cet aspect en menant une étude d’association pangénomique 
et en examinant les séquences exomiques d’individus avec des mesures de densité extrême. Notre 
étude d’association pangénomique n’a pas conduit à la découverte de nouveau loci, probablement 
parce que la taille de notre échantillon, et donc notre puissance statistique, était limitée. En revanche, à 
travers notre approche de priorisation, nous avons découvert un marqueur intronique qui contrôle 
l’expression d’ATP2B4, la protéine principale de transport de calcium dans les hématies. Notre 
séquençage exomique a identifié deux mutations rares faux-sens chez un même patient; l’une dans 
ATP1B2, un transporteur de Na+/K+, et l’autre dans SPTB, le gène du -spectrin. Ces mutations 
expliqueraient pourquoi ce patient a le pourcentage de densité le plus élevé parmi tous nos patients 
séquencés, et pourquoi il vit avec plusieurs complications de la maladie. Finalement, nous avons 
localisé une mutation faux-sens rare chez deux patients avec un indice élevé de densité de globule 
rouge, dans PIEZO1, le canal ionique mécano-sensitif. La mutation est prédite délétère par deux 
algorithmes de prédiction de fonction protéique.  
 
Mots-clés: Analyse pangénomique, séquençage d’exome, anémie falciforme, densité des globules 
rouges, hydratation des hématies, eQTL. 
.
 iv 
Abstract 
 
Sickle cell disease is one of most common blood disorder amongst human. The complications 
associated with the disease are systemic. They damage virtually all the organs of the body, causing 
severe, unpredictable pain episodes, which repercussions can eventually lead to death. The process 
through which a biconcave, healthy red blood cell assumes a crescent-shape is well described in the 
literature; under deoxygenation, as water and solutes leave erythrocytes the concentration of 
hemoglobin S increases thus giving us dense dehydrated cells and subsequently sickled cells. Today’s 
current therapies are for the most part experimental, costly, and vary widely in their long-term 
effectiveness from patient to patient. There is, therefore, a pressing need, to identify a biomarker that is 
cost-effective and provides positive health outcomes to patients. The density of red blood cell is a 
biological indicator largely ignored by the medical community in sickle cell disease. Exploring 
erythrocytes density can facilitate the development of new therapies by targeting channels to rehydrate 
cells back to their normal shape. Clinical and physiological characterizations of this phenotype exist in 
many studies, but the genetic characterization is absent. We attempted to elucidate the genetic 
underpinning of this phenotype, by conducting a genome-wide scan, and examining the whole-exome 
sequences of individuals with extreme red blood cell density. Our genome-wide association study did 
not highlight any new loci due to our limited statistical power reflected by the cohort’s small sample 
size. However, our prioritization approach highlighted an intronic variant that controls the expression of 
ATP2B4, the main calcium pump in erythrocytes. Our whole-exome sequencing experiment pointed out 
two rare missense mutations in the same patient; one in ATP1B2, a Na+/K+ transporter, and the other in 
SPTB, the -spectrin gene. These variants could explain why he has the highest measured density of red 
blood cells amongst all of our sequenced patients, and why this person experiences several of the 
disease-related complications. Another rare missense mutation in two patients with elevated levels of 
dense cells was discovered in PIEZO1, the mechanosensitive ion channel. The mutation is predicted to 
be deleterious by both protein function prediction algorithms.  
 
Keywords: Genome wide association, whole-exome sequencing, sickle cell disease, erythrocyte 
density, red blood cell hydration, eQTL. 
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1. Introduction 
1.1 Sickle Cell Disease Historical Background 
Sickle cell disease (SCD) was first described more than a 100 years ago in Occidental 
literature, by a cardiologist named James B. Herrick while tending to a dental student who 
complained about chest pain. In 1910, he published what is considered today the first report in 
a medical journal describing red blood cells with an odd shape, as seen in Figure 1, which he 
called “sickle-shaped cells”1,2. In 1927, E. Vernon Hahn and Elizabeth Biermann Gillespie3 
were the first to discover the relationship between red blood cells and low oxygen. Three years 
later, Scriver and Waugh determined that in the absence of oxygen, red blood cells become 
sickled4. About twenty years later, in 1948, Janet Watson was the first scientist to elucidate the 
protective role of fetal hemoglobin (HbF)5 on the disease noticing that newborns with the 
disorder did not display any of the known complications. That same year, award winning Nobel 
scientist, Linus Pauling6 called “Sickle Cell Anemia, a Molecular Disease” in Science , where 
he explained that the sickling phenomena originated from abnormal hemoglobin (HbS) which 
differed from normal hemoglobin. The following year James V. Neel7  uncovered the recessive 
model of inheritance. The last two historical landmarks of SCD occurred in the 1950s. In 1956, 
Anthony Allison discovered the link between the protective effect of the sickle cell trait and 
malaria8. The second one happened two years later when Vernon Ingram confirmed that the 
abnormal hemoglobin (HbS) differed from normal adult hemoglobin (HbA) by a single amino 
acid which replaced a glutamic acid by a valine amino acid at position 6 of the -globin subunit 
of hemoglobin9. Although previous reports described the process between red blood cell 
deoxygenation and sickling, Ferrone et colleagues10 cemented our appreciation of the process 
by explaining that the abnormal hemoglobin polymerizes under deoxygenation thus disrupting 
the shape of erythrocytes. This body of discoveries contributed to our understanding of the 
molecular basis of sickle cell disease and constitutes the foundation of future investigations of 
SCD in the 21st century.  
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1.2 SCD Burden in Today’s Society 
The two main inherited hemoglobinopathies are: sickle cell disease (SCD), and the thalassemia 
syndromes. On one hand, SCD made distinctive by red blood cell assuming a crescent shape as 
opposed to the normal biconcave disc-like shape (Figure 2). This change in anatomy will cause 
cells to clog up in blood vessels, small capillaries, and to have a shorter lifespan. As a result, 
problems such as kidney damage, stroke, acute pain, skin ulcers, infections, to name a few, will 
ensue. Thalassemia, on the other hand, is characterized by an imbalance in the synthesis of the 
globin chains. Several types of thalassemia exist; the most common ones are α and β 
thalassemia, which cause ailments such as enlargement of the spleen (splenomegaly), 
susceptibility to infections, and more. 
In 2006, the World Health Organization (WHO) recognized SCD as a global health problem11. 
The increase in SCD awareness prompted public health organizations and health professionals 
to implement strategies to reduce infant mortality, which translated into a systematic prenatal 
screening, prescription of antibiotics, and vaccinations for children. However, these pediatric 
Figure 1. Blood Smear of Sickle Cell 
The image was copied from J.B. Herrick (1910). 
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preemptive measures are more accessible to high-income countries compared to low-income 
countries where 1 in 2 neonates will not reach the age of 512. Although the infant mortality has 
decreased in some parts of the world, projections indicate that the global burden of the disorder 
is set to increase, from over 300,000 newborns in 2010 to more than 400,000 by 2050 (Figure 
3)13. Most of this increase in birth will be attributed to the African continent, which accounts 
for 70% of the world’s cases of SCD. This growth in population from Africa is evidence for the 
argument that malaria endemic countries have the highest disease prevalence14. 
While the highest incidence of the trait is attributable to Africa, WHO’s survey from 2011 
found that worldwide 35 million individuals carried a mutant allele of the disease (i.e. 
individuals that are heterozygous for the sickle cell disease mutation). Indeed, we can find 
individuals of Hispanic (South America, Central America, and parts of the Caribbean), 
Mediterranean (such as Greece, Turkey, and Italy), Indian and Arab descent with the sickle cell 
trait. Studies attributes the occurrence of the gene in those populations to migration, which 
introduced the allele in non-malaria endemic regions, and to selective pressure of malaria, 
which increased the survival of individuals who lived to pass on their genes15-18.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Scanning Electron Micrograph of Normal Erythrocyte  
Retrieved as is from Wikipedia. 
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Figure 3. World's Distribution of Infants with SCA 
As seen in Piel et al. (2013). 
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1.3 Red Blood Cell and Hemoglobin 
In mammals, red blood cells are biconcave and disc-shaped. Hemoglobin protein molecule 
depicted in Figure 4 is a 64 kDa complex with four polypeptide chains; two β polypeptide 
chains, and two α polypeptide chains, held together by non-covalent bonds19. The hemoglobin 
tetramer, also known as HbA, or adult hemoglobin, is the most predominant in humans. Each 
globin chain contains a heme group in which the iron atom binds to oxygen as red blood cells 
pass through the lungs and releases it once in peripheral tissues. Carbon dioxide (CO2) is then 
loaded for a return trip to the lungs where it is exchanged for oxygen. Two different gene 
clusters encode the α-globin and the β-globin families. The α-globin locus on chromosome 16 
contains from 5’ to 3’ the embryonic ζ-globin gene and two adult α-globin genes. The β-globin 
locus resides on chromosome 11 and contains from 5’ to 3’ the embryonic gene (also known as 
ε-gene), two fetal γ-globin genes, and the adult genes, δ and β genes. Each of these genes 
combines to become different hemoglobin tetramer form during various stages of development 
(embryonic, fetal, and adult life). Figure 5 illustrates the relative levels of expression of the 
different globins over time during pregnancy on the y-axis and the organs responsible for blood 
cell production (erythropoiesis) on the x-axis. The ε-globin and ζ-globin genes responsible for 
embryonic hemoglobin are produced during the early maturation stage of red blood cells 
(erythroblast) in the yolk sack20. As the fetal liver becomes the site of erythropoiesis, red blood 
cells become more and more mature, with α and γ genes taking over the previous embryonic 
globin genes. At the time of birth in humans, the bone marrow replaces the fetal liver as the site 
of erythropoiesis21. 
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Figure 4. Hemoglobin Molecule 
Copied from the book Inquiry into Life. 
Figure 5. Globin Gene Expression during Development 
Duplicated from Sankaran VG et. al (2013). 
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1.4 SCD and Malaria 
1.4.1 Historical Perspective 
Malaria is a potentially fatal disease caused by a protozoan parasite infection of red blood cells. 
Depictions of the disease symptoms date back more than four millenniums ago, in Chinese 
medical scrolls, Greek documents, Roman writings, and Spanish missionaries memoires22. 
Since then remedies existed to overcome the illness. In China for example, the Qinghao plant 
(Artemisia annua) dispensed to infected individuals is today known to contain artemisinin, an 
effective antimalarial drug particularly in combination with other drugs. In fact, 2015 Nobel 
Prize in Medicine was awarded to Youyou Tu for her work on an artemisinin-based drug, 
which completely cures sick individuals within 72 hours. Additionally, quinine, another potent 
antimalarial drug used today, was administered back in the 17th century in the form of a bark 
tree known as the Peruvian bark as a cure23. The discovery of the parasite, at the time named 
Plasmodium Oscillaria and later renamed Plasmodium Falciparum, came from Nobel-prize 
winning French surgeon, Charles Louis Alphonse Laveran24. His discovery was 
groundbreaking because it was the first time a eukaryotic pathogen was observed in human 
cells. Following his findings, in 1886, Italian scientist Camilo Golgi, found that two other 
species of the parasite caused variable symptoms of malaria22. His fellow countrymen, 
Giovanni Batista Grassi, and Raimondo Filetti ten years afterwards set out to name each of 
them; Plasmodium vivax, Plasmodium malariae25. Simultaneously to Ronald Ross’ discovery 
that the Plasmodium relictum is transmitted by mosquitoes in birds causing avian malaria, a 
joined effort between Italian scientists, lead by Giovanni Batista Grassi, observed that the 
Anopheles mosquitoes act as a vector for the P. falciparum, P. vivax, and P. malariae in 
humans. The scientific inquiries on the parasite life cycle, pathophysiology, therapies, 
complications related to the disease, and resistance of S trait carriers against the Plasmodium 
stemmed from these breakthroughs. Finally, to date, at least 150 species of the Plasmodium 
genus have been discovered to cause malaria in other vertebrates26-30, two of which in humans: 
Plasmodium ovale and  Plasmodium knowlesi.25  
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1.4.2 Pathophysiology 
The symptoms of the disease intensify from parasite to parasite. The P. Falciparum causes the 
most severe clinical manifestations because of its role in the lifecycle in the human body. 
Complications resulting from the infection, include fever, nausea, vomiting, headache, and in 
severe cases seizures, pulmonary embolism, jaundice and renal failure, convulsions, uremia, 
and acidosis.31 The pathogenesis of the Plasmodium in humans has been extensively 
documented by Ricardo T. Gazzinelli et al32 and more recently by Samuel Crocodile Wassmer 
et al33.  
1.4.3 Burden and Protection 
Despite recent claims of malaria mortality reduction (from 21% to 57%)34,35,36 over the past 
decade, the disease continues to claim hundreds of thousands of lives each year and remains the 
leading cause of death in developing countries. With estimates ranging between 207 and 214 
million new cases every year, the infection is most frequent in Africa (88%), southeast Asia 
(7%) and the Mediterranean region (2%) 35,36. The high prevalence of malaria in Africa can be 
attributed to the selective pressure, which caused germline mutations to confer a survival 
advantage against the disease. In fact, since Anthony Allison’s discovery of the protective 
capability of the sickle cell trait against malaria, studies have attempted to uncover the exact 
biomolecular mechanism through which the -globin mutation hinders the parasite life cycle in 
the human body. Several genetic determinants are thought to shield from the parasite; 
genotypes A/E, A/C, C/C and C, E mutations prevent the parasite multiplications 
through its interaction with low oxygen or reduce adherence to erythrocytes37,38. Additionally, 
two erythrocyte enzymes deficiency; G6PD (glucose-6-phosphate dehydrogenase deficiency), 
and PKLR (pyruvate kinase) are thought to lessen the density of the Plasmodium, the first one 
through oxidative stress while the second one through inhibition of its replication in vitro.39 
Moreover, National Institute of Health (NIH) group lead by Miller LH found that platelet 
glycoprotein 4, also known as CD36, sequester the plasmodium parasite inside erythrocytes and 
compromises its immune system40. Several other hypothesis and mechanism involving heme-
oxygenase 1 (HMOX1), or the interactions between higher levels of carbon monoxide and 
hemoglobin S41 (Figure 6), and other molecules were put forward, without necessarily being 
21 
 
confirmed in humans on a large scale42-44 . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Biomolecular Model of Malaria Protection  
Copied from Ferreira et al. (2011) 
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1.5 Pathophysiology of Sickled Cells 
Hemoglobin S (HbS) polymerization is the chief and initial phenomenon in SCD 
pathophysiology. Upon the removal of the oxygen atom and dehydration of erythrocytes, the 
hemoglobin molecule becomes sticky and starts to form rod-like structures. Erythrocytes then 
become rigid, dehydrated and eventually assume a sickle shape. While the polymerization 
process is initially reversible, after multiple cycles of sickling, the blood cells become 
irreversibly sickled (IRS). These cycles, in turn, have some significant effects on red cell 
membrane structure, function, and adherence to the vascular endothelium, which will lead to 
the trapping of red blood cells and leucocytes in small capillary beds. According to Rees et 
al.45, and as seen in Figure 7, there are two major pathways involved in the manifestations of 
the complications related to SCD. The first one is a direct consequence of cells being trapped in 
blood vessels and of the endothelium becoming sticky. This obstruction of blood vessels, and 
increase adhesiveness of the endothelium causes complications such as acute pain, 
nephropathy, inflammation, and pulmonary hypertension to name a few. The second pathway is 
the result of red blood cells bursting and therefore releasing hemoglobin, which will bind nitric 
oxide (NO)46. Hemolysis is the source of complications such as leg ulcer, priapism, stroke and 
chest pain45. The sickling rate in erythrocytes is directly correlated with the intracellular 
concentration of HbS, which can be reduced by the presence of fetal hemoglobin (HbF) as seen 
in individuals with the hereditary persistency of fetal hemoglobin (HPFH) genotype. Indeed, 
different alleles other than the -globin mutation can influence HbS concentration and either 
raise or lower the polymerization rate. We find three main SCD genotypes. The first one is 
sickle cell anemia (SCA) groups together all individuals with homozygous -globin mutation 
(S/S) which depending on reports and populations’ ethnicity can vary from 36.4% to 95.7%47.  
The second genotype consists of heterozygous (S/C) with allelic frequency ranging from 
3.6% to 92.2% depending on ethnicity and reports. The final genotype consists of S and -
thalassemia (S/0) which is widespread mostly in Arabs (~28%), and in Indians (~30% and 
~63%), but has a low frequency in Africans (~0.7%)47. Other genotypes of the disease can 
occur, as described in Table1 below.  
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Severe sickle-cell disease Characteristics 
HbS/S (β6Glu>Val/ β6Glu>Val); 
sickle-cell anaemia 
The most common form of sickle-cell disease 
HbS/β0 thalassaemia Most prevalent in the eastern Mediterranean region and 
India48 
HbS/OArab 
(β6Glu>Val/ β121Glu>Lys) 
Reported in north Africa, the Middle East, and the 
Balkans; relatively rare48 
HbS/D Punjab 
(β6Glu>Val/ β121Glu>Gln) 
Predominant in northern India but occurs worldwide48 
HbS/C Harlem 
(β6Glu>Val/ β6Glu>Val/ β, β73Asp>Asn) 
Electrophoretically resembles HbSC, but clinically severe; 
double mutation in β-globin gene; very rare49 
HbC/S Antilles 
(β6Glu>Lys/ β6Glu>Val, β23ValIle) 
Double mutation in β-globin gene results in severe sickle-
cell disease when co-inherited with HbC; very rare50 
HbS/Quebec-CHORI 
(β6Glu>Val/ β87Thr>Ile) 
Two cases described; resembles sickle-cell trait with 
standard analytical techniques51 
Moderate sickle-cell disease 
HbS/C   
(β6Glu>Val/ β6Glu>Lys) 
25-30% cases of sickle-cell disease in populations of 
African origin52 
Moderate HbS/ β+ thalassaemia Most cases in the eastern Mediterranean region; 6-15% 
HbA present48 
HbA/S Oman 
(βA/ β6Glu>Val, β121Glu>Lys) 
Dominant form of sickle-cell disease caused by double 
mutation in β-globin gene; very rare50 
Mild sickle-cell disease 
Mild HbS/ β++ thalassaemia Mostly in populations of African origin; 16-30% HbA 
present48 
HbS/E 
(β6Glu>Val/ β26Glu>Lys) 
HbE predominates in southeast Asia and so HbSE 
uncommon, although frequency is increasing with 
population migration53 
HbA/Jamaica Plain 
(βA/ β6Glu>Val, β68Leu/Phe) 
Dominant form of sickle-cell disease; double mutation 
results in Hb with low oxygen affinity; one case 
described54 
Very mild sickle-cell disease 
HbS/HPFH Group of disorders caused by large deletions of the β-
globin gene complex; typically 30% fetal haemoglobin48 
HbS/other Hb variants HbS is co-inherited with many other Hb variants, and 
symptoms develop only in extreme hypoxia 
Table 1. Different Types of Sickle Cell Disease  
Copied as is from Rees DC, et al (2010). Genotypes that have been reported to cause sickle-cell disease are listed. All include 
at least one copy of the βS allele, in combination with one or more mutations in the β-globin gene. HbS=sickle haemoglobin. 
HbA=haemoglobin variant A. HbE=haemoglobin variant E. Hb=haemoglobin. 
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Figure 7. Pathophysiology of Sickle Cell Disease 
Copied from Rees DC, et al (2010) 
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1.6 Complications of Sickle Cell Disease 
As mentioned before, SCD is a systemic disorder affecting multiple organs. These include the 
cardiovascular system (chronic myocardial insufficiency), the digestive system (chronic liver 
disease, gallbladder dysfunction), the urinary system (nephropathy), the nervous system 
(cerebral infarction), the male reproductive system (priapism), the ocular system (retinopathy), 
the skin system (leg ulcers), the blood system (splenectomy), and the respiratory system (acute 
chest syndrome). The National Heart Lung and Blood Institute website at the National Institute 
of Health identifies 18 major inter-related complications to SCD55. Although children show no 
sign of the disease until they are 5 to 6 months old due to HbF’s protective effect, some of the 
first most common complications newborns are likely to experience include: dactylitis (aching 
and swelling of hands and feet), anemia (manifested by fatigue), and jaundice (yellow coloring 
of skin and eyes due to hemolysis of cells)56. Below are the four overarching complications, 
each with the specific organs they affect and their manifestations: 
 
 Acute Pain 
o One of the major complications and a sure sign of SCD is the acute pain episode 
18,57. Pain crises are sudden, unpredictable, and are attributable to erythrocytes being 
entangled in blood vessels, thus, reducing the supply of oxygen to tissue organs. The 
pain episodes, can therefore be felt at any location on the body, and have been 
described as intense, agonizing, excruciating aches that can require hospitalization.  
o Acute chest syndrome is another well-characterized complications of SCD58,59. It 
ensues from vaso-occlusion of erythrocytes in the lungs, which prevents the 
provision of oxygen to capillaries, which will, in turn become damaged. Acute chest 
syndrome’s symptoms resemble those of pneumonia and often lead to 
hospitalization of the individual. This complication is so severe that it is the leading 
cause of deaths in adults. 
o An hour long lasting painful erection without sexual arousal (priapism) is a frequent 
complication in males with SCD. Priapism persisting more than three hours is 
called prolonged priapism (PP), whereas when there are intermittent relapsing 
attacks of lasting two to six hours it is known as stuttering priapism (SP). 
Severity or recurrence of either SP or PP can end in penile fibrosis and 
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impotence.  
 
 Chronic Pain 
o Bone and joint-related complications in SCD patients are debilitating. Usually 
widespread amongst teenagers, both osteoporosis, and bone marrow expansion are 
common60. Osteonecrosis results from bone infarction, and is one of the leading 
causes of chronic pain in adults with devastating effect on the quality of life. Bone 
marrow infarction is a result of an acceleration of the production of blood cells 
(hematopoiesis), which can lead to reticulocytopenia (also known as aplastic crises, 
the decrease production of reticulocytes), a release of immature leukocytes and 
erythrocyte in the blood (known as leukoerythroblastic anemia).  
o The advent of adolescence and the presence of severe anemia may enable the rate of 
leg ulcers61,62. These ulcers are more often reported in patients with S/S genotype 
than with S/C (22% and 9% respectively)63. Plus, lifetime occurrence of ulcers can 
vary from patient to patient. 50% of individuals will experience leg ulcer once in 
their lifetime, another 25% will experience them once to twice a year over several 
years, and finally the remaining 25% will experience leg ulcers chronically with 
multiple relapses64. Due to inflammation, scarring, and infection that accompany the 
complications, leg ulcers can be very painful. While high levels of HbF improve the 
condition, low hematocrits count (HCT), with increase hemolysis and manhood are 
additional risk factors for developing leg ulcers65. Moreover, a Jamaican cohort 
study of 225 patients showed that the occurrence of leg ulcers is increased at 18 
years of age66. 
 
 Vascular Disorders 
o Brain related complications also manifest themselves in SCD patients. These can be 
broken down into two types of complications: clinical strokes and silent strokes. 
Clinical strokes, which are due to a loss of the blood circulation to an area of the 
brain and cause tissue damage, are called ‘clinical’ strokes because their onset is 
noticeable and identifiable when they occur. Symptoms include seizures, single-
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sided weakness or numbness/tingling, loss of balance, vision, and slurring of 
speech. One severe form of clinical stroke is known as intracerebral hemorrhage, 
which is the result of the breakage of an aneurysm that can lead to sudden death. 
The second form of brain related complications is the silent strokes, also known as 
silent brain infarct. These are a temporary loss of blood flow with unnoticeable 
symptoms of stroke causing brain lesions. In term of incidence, 35% of individuals 
will be affected by one of the types of brain vasculopathy, with 10 to 15% of them 
being under the age of 1067. Transcranial Doppler (TCD) screening is an effective 
method for cerebral vasculopathy68. 
o Eye problems or retinopathies are common for SCD patients. Goldberg et al. 69 have 
divided a classification system to assess the progression of retinal complications in 
SCD. Stage 1 consists of a simple peripheral inadequate blood supply with arterial 
occlusion. Stage 2 features the degradation of ocular capillaries, with a benign 
change in vasculature near the retina. Stage 3 consists of the formation of functional 
microvascular networks with red blood cell perfusion known as neovascularization. 
Finally, stage 4, marks the leakage of blood into the areas in and around the vitreous 
humor of the eye, which can lead to a detachment of the retina.  
 
 Organ insufficiencies and other complications 
o Renal complications or nephropathy are well characterized in SCD. Often times, 
renal manifestations are due to kidney’s tubular malfunction, thus causing improper 
acid excretion, inappropriate uric acid elimination, and inefficient potassium 
regulation. It is estimated that 18% of SCD patients will experience renal failure 
over their lifetime. The presence of blood in the urine (hematuria) occurs more often 
in individuals with the S/C genotypes as opposed to S/S. Hematuria results from 
the death of renal papillary tissue, but can also be due to the formation of stony 
mass (calculi) in the body, tumor, or infection70,71. Additionally, the presence of 
protein in urine (proteinuria), the presence of albumin in urine (albuminuria), excess 
of uric acid in the blood and attacks of gout are the consequence of glomerular 
dysfunction, an acquired dysfunction in SCD.  
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o The other major category causing complications is severe anemia. Different degrees 
of anemia affect individuals with SCD. However, severe anemia, which manifests 
itself mainly in infants less than ten years of age, is life-threatening and can be 
caused by acute splenic sequestration crisis. The crisis presents itself as an 
enlargement of the spleen that is due to considerable drop in hemoglobin levels 
brought about by acute blood entrapment within the splenic tissue72. Moreover, 
aplastic crisis can also lead to severe anemia. The main cause of this predicament is 
parvovirus B19 infection, which in SCD patients causes a disruption of red blood 
cell production leading to severe anemia73. 
o Irrespective of the patients’ age, infections are a recurrent theme for SCD patients. 
With the activity of the spleen being compromised early in their lifetime, patients 
are more at risk of contracting deadly bacterial infections74,75. These can cause 
blood infection (septicemia), lung infection (pneumonia), infection of the membrane 
covering the brain and spinal cord (meningitis), and bone infection (osteomyelitis).  
 
1.7 Known biomarkers of severity in SCD 
According to the NIH Biomarkers Definitions Working Group definition from 199876, 
biomarkers (a contraction of the word biological and markers), is defined as an unbiased 
observation or measure which can be used as an indicator of a diseased or natural biological 
process or drug response. Their critical role in biomedical research stems from their impact on 
enhancing drugs effectiveness, and their relevance in helping understand basic science research. 
Based on the currently available reviews of biomarkers in SCD 77,78, these indicators are 
categorized based on the pathophysiology of SCD, some are more functional than others (i.e., 
biomarkers of red cell rigidity vs. total hemoglobin), and some are interrelated (i.e., red cell survival 
and reticulocyte count). Figure 8, illustrates the physiological pathways of SCD starting from 
hemoglobin polymerization. The red boxes show the originator processes with red blood cell 
density (DRBC) highlighted in red inside the red cell hydration biomarkers box. The bright green 
boxes are the outcomes of interrelated processes. This summary points to the fact that using DRBC 
as a biomarker for SCD positions us early enough in the course of sickling that we may be able to 
reverse it. We believe that as more and more reseachers explore this biomarker and initiate clinical 
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trials, it will become more central in the efforts to treat SCD.  
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Vasculopathy and Endothelial 
Dysfunction 
 Triglycerides 
 Apolipoprotein A-1 
 Vascular endothelial growth factor 
(VEGF) 
 Placental growth factor (PGF) 
 Endothelin-1 
Oxidative Stress and Reperfusion Injury 
 Red cell glutathione and glutamine 
 Modified serum albumin 
 Thiobarbituric acid reacting substances (TBARS), 
tocopherol 
 Malondialdehyde (MDA), eicosanoids 
Inflammation 
 C-reactive protein (CRP) 
 Erythrocyte sedimentation rate (ESR) 
 Secretory phospholipase A2 (sPLA2) 
 Interleukins (IL2, IL3, IL6, IL8 and 
IL10) 
 Urinary cysteinyl 
 Leucotriene E4 
 Serum levels of prostaglandin-E2 
 CA 15-3 
 Soluble CD40 ligand 
 HSP-70 
 Ferritin 
 Angiopoietin 1 and 2 
 Stromal derived factor 1 
 Tumor necrosis factor-α and receptor 1 
Hemolysis 
 Serum Lactate dehydrogenase 
 Aspartate transaminase 
 Haptoglobin 
 Free plasma HGB concentration  
 RBC survival 
 Reticulocyte Count 
 
HbS Polymerisation 
 HbF 
 MCH (indicates co-inheritance of α-thalassemia) 
Red Cell Hydration 
 Sickled cells count on blood film 
 Red cell density (DRBC) 
 
Adhesion 
 Increased red cell 
 Phosphatidylserine and phosphatidylethanolamine 
 Reticulocyte CD36 expression 
 Reticulocyte integrin α4β1 
 White blood cell 
 Total white cell count 
 L-selectin and αMβ2 
 Adhesion molecule 
 sICAM-1, sVCAM-1, P-selectin, E-selectin, Fibronectin 
Anaemia and Hypoxaemia 
 Total HGB 
 Erythropoietin 
 
Hypercoagulation 
 D-dimer 
 Thrombin-antithrombin 
 Prothrombin fragment F1 + F2 
 Fibrinopeptide A 
Nitric Oxide Metabolism 
 Nitrite and Nitrate 
 L-arginine 
 Plasma arginase 
 Plasma arginine: ornithine ratios 
 Asymmetric dimethylarginine 
(ADMA) 
Organ damage 
 Cardiac Disease 
 NT-pro brain natriuretic peptide (NT-proBNP) 
 Cardiac troponin I 
 Hyposplenism 
 Pitted red cell count 
 Howell Jolly body quantitation by flow cytometry 
 Renal dysfunction 
 Haematuria 
 Blood urea 
 Cretonne concentrations 
 Urine albumin:creatinine ratio or protein:creatinine ratio 
 Cystatin C 
 Urinary kidney injury molecule-1 
 Urinary N-acetyl-b-D-glucosaminidase 
 Urinary transforming growth factor-β1 
 Urinary kallikrein 
 Urinary endothelin-1 excretion 
 Bone Disease 
 Vitamin D 
 Alkaline phosphatase 
 Pyridinoline and deoxy-pyridinoline 
Figure 8. Sickle Cell Disease Biomarkers 
Adapted from Rees, D. C. and J. S. Gibson (2012). 
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1.8 Therapies in SCD 
Although gene therapy shows promising signs79,80, the treatment remains in its early stages of 
development and is considered to be out of reach for most. Therefore, as of today, there is no 
official and readily available cure for individuals with SCD.  
 
1.8.1 Hydroxyurea (HU) 
HU is the treatment of choice in sickle cell disease, its goal is to stimulate the production of 
HbF in patients81-83. Remaining the only FDA approved drug for the therapy of the disease, it 
has been shown to reduce acute chest syndrome episodes, the number of hospitalizations and of 
blood transfusions in all age groups84-88.  Moreover, it has been proven successful in decreasing 
mortality in a group of severely affected patients after a 5 to 10 years’ follow-up88. 
Nevertheless, the drug is still considered as a half way measure since there are no clear benefits 
on the risk of stroke89, priapism, renal complications, as well as pulmonary and cardiac 
insufficiencies. In addition, several severe side effects exist; myelotoxicity (which is the 
decrease in production of cells responsible for providing immunity, carrying oxygen, and/or 
those responsible for normal blood clotting (thrombocytes)), leg ulcers, and low sperm count 
(oligospermia)90-92.  
 
1.8.2 Bone Marrow Transplant 
Bone marrow transplantation is another accepted therapy in SCD, yielding 80-90% disease free 
survival93-96. It is similar to receiving a blood transfusion, however, the cost of the procedure, 
the need to identify a sibling compatible donor (or human leucocyte antigen identical donor), 
the necessity of going through chemotherapy, and to take immune suppressor considerably 
limits the number of patients who can access the therapy.  
 
1.9 Genome-Wide Association Studies (GWAS) of Sickle Cell Disease  
GWAS are a powerful tool to explore the genetic architecture of human disease. In essence, 
genetic associations refer to the association test between a SNP and a trait. The traits can be 
categorical (e.i., having or not having type 2 diabetes) or quantitative (i.e., height, weight, high-
density lipoprotein cholesterol, low-density lipoprotein cholesterol). For a given trait, the 
association will be significant if the disease frequency varies according to the genotype. In 
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other words, when testing a specific allele T, at an T/C biallelic SNP, we will find more cases 
than controls or a correlation with a quantitative trait for a significant association97. Thanks to 
the advent of cost-effective massively parallel genotyping arrays able to genotype upwards 2.4 
millions SNP, and the cataloguing of human polymorphism in project such as the 1000 
Genome project98, the HapMap project99, and more recently the Haplotyple Reference 
Consortium100, we have witness a considerable increase in the number of association studies. 
As of 2014 the National Human Genome Research Institute Catalogue of published GWAS101 
indexes close to 2,000 curated publications, 12,000 SNPs for more than 200 traits. This 
profusion in genome wide scans is in stark contrast to 2005, at the eve of the completion of the 
human genome project102,103 when just very few publications and loci were reported. GWAS 
confers a true advantage compare to linkage studies and candidate gene analysis, as they give 
the ability to interrogate the whole genome in a systematic manner97. 
One of the early successes of GWAS dates from 2005 with the identification of the 
Complement Factor H gene as a major risk factor for age-related macular degeneration104-106 in 
studies of 146 patients with 90 cases, and about 100,000 SNPs. Nowadays, with the 
implementation of imputation in GWAS analysis pipelines, and extensive collaborations meta-
analyses never conceived before are now undertaken. For example, the recent meta-analysis of 
blood traits in the UKBiobank107 which consisted of a sample size of ~200,000 patients, with 
29.5 million markers, and the one on body mass index which included over 300,000 individuals 
and tested over 2.5 millions SNPs108. 
In SCD research, early association studies that focused on acute chest syndrome, priapism, 
osteonecrosis, and pain crises yielded spurious results109. However, SNPs in UGT1A1110 and 
MYH9–APOL1111 were associated with gallstones, and renal failure respectively in SCD 
patients and replicated in other cohorts. The presence of replication for these findings provided 
the first loci for SCD complications. The majority of other successful GWAS in SCD 
implicated discoveries with HbF. Namely the link between HbF and BCL11A112,113, and 
subsequently between HbF and BCL11A, HBS1L-MYB, and HBB114-116 which together account 
for 50% of the heritability of fetal hemoglobin117. 
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1.10 Density of Red Blood Cell in Sickle Cell Disease 
 
1.10.1 Biology and Physiology of Red Cell Hydration 
 
Before 1950 the role of moving solutes and water across red cell membrane was attributed to 
calcium-dependent potassium channels in general118. However, since the discovery of the 
Gardos channel, a calcium-activated potassium channel, our understanding of the importance of 
this channel on ion homeostasis has significantly improved. In fact, today, our comprehension 
of the transport mechanism involved in erythrocyte osmoregulation extent to designing 
pharmaceutical drugs to target these channels. Studies have found that in red cells both the 
volume, and the hemoglobin concentration are dependent on the cation, anion content, as well 
as the water amount. Cation content regulation involves two active and two passive transporter 
membrane proteins. The sodium-potassium-ATPase pump and the calcium-ATPase pump are 
the two ATP-dependent transporters that move sodium and calcium outside of erythrocytes 
either in collaboration with passive transporters or on their own. Although loss-of-function 
mutation and missense mutation have been reported to cause hemiplegic migraine type 2 and a 
type of Parkinson disease119,120, scientific inquiries pinpointed the calcium-activated potassium 
channel to play an important role in the dehydration of erythrocytes in SCD121-123. Passive 
cation transporters rely on the external and internal concentration of potassium to become 
active, which why they are labeled co-transporters. The two co-transporters reviewed in human 
erythrocytes are the sodium-potassium-chloride co-transporter (Na+/K+/Cl-), and the potassium-
chloride (K+/Cl-) co-transporter. Reports indicates that the latter, the electroneutral co-
transporter, plays an essential part in erythrocyte dehydration in SCD either by itself or in 
conjuction with the Gardos Channel. Knockout models and molecular characterization of all of 
its isoforms (KCC1, KCC2, KCC3, KCC4) shed light on its impact. Of interest, knockout 
mouse KCC3 (-/-)124 results in dysfunctional cell volume regulation in neurons and kidney 
tubular cells, which is accompanied by a loss of hearing acuity, and neurological disorders. 
Additionally, knockout KCC4 (-/-)125 lead to deafness and tubular acidosis, and KCC2 (-/-)126 is 
lethal just after birth due to respiratory failures. Additional cation transporters include sodium-
hydrogen (Na+/H+) exchanger, and sodium-magnesium (Na+/Mg+) exchanger. The Na+/H+ 
exchanger is crucial for the regulation of intracellular pH and cell volume127, and was found to 
be up-regulated in mice with spherocytosis. The second cation exchanger, regulates magnesium 
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content in erythrocytes and may be to incriminate for the low levels of magnesium found in 
SCD individuals. When it comes to the regulation of anion content the only protein known to 
be involved is the anion exchanger band 3128,129. Several functional roles have been identified 
for the protein, including; chloride-bicarbonate exchanger (Cl-/HCO3-), transporter of carbon 
dioxide (CO2) from tissues to the lungs’ alveoli, and stabilizer of red cell cytoskeleton. In vitro 
studies and DNA mutations analysis in this gene have been associated with severe health 
outcomes, such as spherocytosis, hemolytic anemia, splenectomy, and renal dysfunction130-132. 
Finally, water content moves freely across red blood cell membrane without the need of any 
energy input but it can be rushed through the water channel known as the aquaporin 1 (AQP-
1)133. The water content generally depends on osmotic pressures, and solutes (Na+, K+, Cl-) 
concentration. Figure 9 describes the different channels controlling red cell hydration.  
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Figure 9. Control of Red Cell Hydration 
Retrieved as is from UptoDate webpage on Control of red cell hydration. The figure is a schematic representation of the transport 
mechanisms regulating red cell hydration. The extracellular concentrations of sodium and calcium are higher than those within the cell, 
creating favorable gradients for entry, while the intracellular concentration of potassium is higher than that in the extracellular fluid, 
creating a favorable gradient for potassium exit by the K-Cl cotransporter or the calcium-activated (Gardos) potassium channel. The red 
transporters are active, the blue transporters are passive. Band 3 protein primarily functions as a Cl-HCO3 exchanger. Its primary 
physiological function is to facilitate CO2 transport from tissues to alveoli; it also plays an important role in defining red cell shape and 
membrane stability. Water movement passively follows that of cations and anions, or changes in tonicity of the red cell's environment. 
Transport of water can occur at a much faster rate via water channels (aquaporin-1, Aqp-1). 
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1.10.2 Sickle Cell Disease and Clinical Trials 
To summarize red blood cells volume is dependent on osmotic pressures, which are dependent 
on water content, and solutes concentrations. In SCD, the literature shows that three primary 
pathways are involved in cell dehydration:  
 
 The potassium-cloride co-transporter or KCC pathway, a key regulator in the 
dehydration of sickle red cells, playing a role alone or cooperatively with the Gardos 
channel134-136. When sickled cells are in contact with the renal medullary environment, 
they cause leakage of potassium, chloride, and water. KCC has four isoforms 
SLC12A4/KCC1, SLC12A5/KCC2, SLC12A6/KCC3, and SLC12A7/KCC4, which are 
all present in human erythrocytes.  
 The Gardos channel, or KCNN4, activates under deoxygenation and sickling when the 
red cell membrane is more permeable to calcium. This will push chloride out of the 
membrane leading to further sickling. Some in vitro studies have shown that the 
calcium-dependent channel causes red blood cell to become irreversibly sickled and 
contribute to the vaso-occulusive process137,138. 
 The deoxygenation-induced pathway leads to dehydration because it causes the cell 
membrane to become permeable to calcium thus activating the Gardos Chanel. 139-141. 
 
The density of red blood cell is a biomarker that captures the modification of intracellular HGB 
concentration and red cell dehydration. This biomarker is crucial in understanding the 
modulation of hemoglobin S in SCD and designing therapeutic drugs142 to prevent dehydration 
or increase hydration. Indeed, Ishii et al143 described the mechanism through which the 
calcium-activated potassium channel regulates the dehydration of erythrocytes. Upon activation 
the Gardos channel, which causes an increased intracellular calcium levels, potassium and 
water are forced out of the cell, therefore dehydrating it and raising HbS concentration. 
Bartolucci et al144 who reported dense red blood as a cell with decreased water content, and 
increased MCH, provided empirical evidence of the role of DRBC in SCD complications. Their 
analysis on dense erythrocytes in ~500 SCD patients for the first time established the negative 
link between DRBC and complications such as renal dysfunction, priapism, and leg ulcer. 
Moreover, to strengthen the relationship between dense red blood cells and SCD, he showed 
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that after six months of hydroxyurea usage the population of dense cells decreases by 34%. 
Both the Bartolucci’s study and the role of the Gardos channel in red cell dehydration in the 
context of sickle cell provide evidence that the density of erythrocytes leads to complications, 
and that a specific protein could be involved in the process of SCD pathology. In fact, using 
antifungal drug, clotrimazole, in transgenic mice the Gardos channel was successfully inhibited 
leading to a reversal of dehydration and potassium loss145,146. Plus, a clinical investigation with 
the same therapeutic agent administered to 5 sickle cell anemia individuals was found to 
effectively inhibit cell dehydration and potassium loss147. Another trial consisted in giving oral 
supplement of magnesium pidolate148 to 17 SCD patients. Although this pilot study resulted in 
an increase in cell volume, a decrease in hemoglobin concentration, and reduction in the rate of 
pain crises149, it seems to raise the concentration of circulating hemoglobin. More recently a 
phase III clinical trial of 144 people with Senicapoc (ICA-17043)150 a Gardos channel blocker 
was found to improve erythrocyte survival (e.i., hematocrit levels, and reticulocyte count), to 
reduce the number of dense red blood cells, and hemolysis. The trial didn’t move to phase IV 
because it didn’t have any impact on pain crises. 
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1.11 Research Objectives and Thesis Outline 
Given the clinical heterogeneity of SCD, and that erythrocyte dehydration is a typical feature of 
the disorder, in this thesis, we attempted to identify the genetic factors contributing to the 
disease severity through red cell density. We hypothesize that DRBC, a precursor to red blood 
cell sickling, explains the clinical variability of SCD manifestations. We first performed a 
genome-wide association study to identify common variants with modest-to-weak effect size, 
prioritizing markers falling within erythroid enhancers, expression quantitative traits locus 
(eQTL) in candidate genes, and variants associated with MCHC. We then singled out variants 
based on their significance thresholds for further analysis. Finally, we sequenced the exomes of 
a subset of our cohort to identify rare variants in candidate genes with high penetrance using a 
variant scoring scheme and available bioinformatics annotations. 
 
1.12 Thesis Outline 
In Chapter 2, I provided a description of the GEN-MOD cohort detailing demographic 
information, sample size for hematological traits, and complications. Additionally, I reviewed 
the genotype imputation method, the normalization of DRBC, the quality control measures 
employed in the genotyping, and the whole-exome sequencing experiments. I also, provided an 
overview of the statistical methods used in genome-wide association testing. Finally, the 
chapter ends with a breakdown of the bioinformatics tools utilized to carry out the analyses 
presented in the thesis. Chapter 3 presents the methods, discussion as well as the association 
results of DRBC in sickle cell disease patients. Chapter 4, describes the methods, results and 
discussion of the whole-exome sequencing analysis. Finally, chapter 5 concludes the thesis 
summarizing and discussing all the key findings, and puts forward guidelines for future 
experiments. 
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2. Methods 
 
2.1 Sample Size  
 
The Genetic modifier study (GEN-MOD) is a cohort of African individuals from the West 
Indies, Sub-Saharan Africa, and Central Africa recruited in France as described in Bartolucci et 
al144. The cohort included 185 men, and 223 women, with a median age of 30 (± 9) (Table 2 
below describes the available blood traits, and complications). Our final dataset consisted of 
403 patients selected for genotyping. One individual was removed during genotyping QC, and 
an additional twenty-eight that were dropped due to DRBC missing values.   
 
Table 2. GEN-MOD Cohort Description 
 
The table below describes the GEN-MOD cohort by sample size for hematological traits, and SCD-
related complications. Additionally, it presents the median with standard deviation whenever possible. 
Blood traits Sample Size Median (± SD) 
DRBC 374 13.1 (± 8.6) 
Basophils 407 1 (± 0.9) 
Eosinophils 407 2 (± 2.8) 
Hematocrit 407 26 (± 4.6) 
Hemoglobin 399 8.8 (± 1.3) 
HemoglobinA 408 0 (± 3) 
HemoglobinA2 408 3.4 (± 0.7) 
HemoglobinF 408 5.6 (± 4.8) 
HemoglobinS 408 84.7 (± 6.0) 
Lymphocytes 407 35 (± 10.7) 
MCH 400 30 (± 4.1) 
MCV 407 87 (± 10.2) 
MPV 356 8.6 (± 1.04) 
Metamyelmyel 392 0 (± 0.4) 
Monocytes 407 7 (± 3.8) 
NucRBC 402 1 (± 7.6) 
Platelets 407 382 (± 120.8) 
Polys 407 55 (± 11.32) 
RBC 408 3.01 (± 0.78) 
Reticulocytes 405 81 (± 46.9) 
Whitebloodcount 407 10.2 (± 3.7) 
   
Complications Sample Size (Control/Cases) - 
Aseptic Necrosis 237/94 - 
Leg ulcer 301/30 - 
Cholecystectomy 207/201 - 
Stroke 394/14 - 
Priapism 107/42 - 
Retinopathy 67/182 - 
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2.2 Phenotype Quality Control 
 
To establish a link between genotype and phenotype in association testing it is common 
practice to use linear mixed models. As one of the main assumptions of these models is that the 
phenotype under consideration follows a normal distribution. When this is not the case, it is 
standard practice for phenotypes to be normalized151. Normalizations account for outliers and 
can involve one of the following: natural log, inverse normal, or square root. We can then 
evaluate confounding factors (age, gender, batch effect and more), fit them with a linear model 
to adjust for them. For DRBC we inverse normal transformed it after adjusting for age, and 
gender using custom R script. Figure 10 below shows the before and after normalization of 
DRBC.  
 
 
 
 
 
 
 
Figure 10. Dense Red Blood Cell Distribution Normalized 
The left most histogram shows that the raw data follows a power law distribution prior to any transformation whereas the 
right most histogram shows that post transformation the data follows a normal distribution. 
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2.3 Genotyping Quality Control 
 
The genotyping quality control (QC) is essential for any association analysis, and it has been 
extensively reviewed by Ziegler et al.152 and by Teo et al.153. The three important steps to apply 
to genotyping QC are SNP quality assurance, sample quality assurance, and population 
stratification assessment. Looking at the SNP quality assurance involves, filtering out 
autosomal variants with a genotyping call rate of less than 95%, variants with minor allele 
frequency (MAF) less than 1% or 5%. Additionally, weeding out correlated variants identified 
by LD threshold, and SNPs out of Hardy-Weinberg Equilibrium (HWE P-value < 1e-7) 
improves the quality of the dataset (variants out of HWE violate the assumption that allele 
frequency and genotype frequency are predictable). Sample quality assurance requires filtering 
out cryptically related individuals, erroneously labeled gender, individuals with a missing call 
rate less than 95% and individuals with over or under heterozygosis rate. Finally, investigating 
the population stratification involves identifying individuals that fall outside of their expected 
ethnicity when comparing them to another population samples dataset through principal 
components analysis (PCA). In this work, multidimensional scaling (MDS) available in 
PLINKv1.07154 was used when comparing the GEN-MOD cohort to the HapMap399 samples 
(Figure 11) because we wanted to make sure we could identify population substructure based 
on genotypic distances. 
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Figure 11. PCA of GEN-MOD against HapMap3 
 (A) First principal component versus second principal component shows that the GEN-MOD cohort aligns as expected with 
individuals from African ancestry. (B) Third principal component versus fourth principal component shows again that the 
GEN-MOD aligns with individuals of African ancestry. (C) First principal component versus second principal component only 
for individuals from African ancestry, shows the difference in ethnicity amongst Africans. 
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2.4 Whole-Exome Sequencing Quality Control 
 
Whole-exome sequencing requires extensive pre-processing, and quality control measure to 
reduce false positives and improve the sensitivity of variant calling. Multiple tools and 
pipelines for whole-exome sequencing exist and have been reviewed by Bao et al155. 
Additionally, different manufacturers provide their own recommendations for cleaning, and 
processing their data, yet they all involve the same steps: 
 Quality control which entails the removal of low-quality reads, PCR primers, adaptors, 
duplicates and other contaminants 
 Mapping reads onto a reference genome 
 Targeted sequencing quality control 
 Quality control of mapped reads 
 Post-alignment processing 
 Variant calling 
  
2.5 Imputation 
 
Genotype imputation is the statistical method to infer genotypes that were not directly typed156. 
The existing implementations (BEAGLE, IMPUTE, and Minimac157-159) rely on hidden 
Markov model to predict untyped markers using both correlation information of typed markers 
and the reference panel. Imputation allows researchers to analyze markers that were not 
previously available in their study, and therefore represent significant cost saving. In a 
comparative analysis that looks at the differences in computation between tools mentioned 
above, pre-phasing160 haplotypes was found to have a dramatic improvement on imputation 
speed for all three methods. In decreasing order of imputation speed, the methods are 
BEAGLE, Minimac, and IMPUTE161. Yet, looking only at factors specific to sensitivity such 
as concordance (percentage that an observed SNP genotype is identical after imputation), 
imputation quality score (IQS162; concordance adjusted for probability of consensus), and 
average r2 156 (correlation between the imputed genotype and the observed), identified Minimac 
and IMPUTE2 as best the performer163. Our dataset increased from ~2.5 million to 31 million 
SNP after we carried phasing with SHAPEIT164 and imputation with Minimac165 using 
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haplotypes from the 1000 Genomes Project.  
 
2.6 Statistical Methods for Association Testing  
 
2.6.1 Power & Replication 
 
Statistical power in GWAS provides the likelihood of observing a true association. Researchers 
attempt to optimize or increase their study power by increasing their sample size, focusing on 
allele frequency and effect size thresholds, and reducing the existing correlation (LD) between 
tested SNPs such that only independent variants are tested166. Testing multiple SNPs increases 
the odds of observing a significant association just by chance, this is known as the ‘multiple 
burden’ hypothesis. Geneticists consider that all associations with a P-value < 5 x 10-8 (i.e. a 
Bonferroni correction for the number of independent loci in the human genome) are deemed 
genome-wide significant166. However, several additional multiple testing corrections exist 
some more stringent than others166-168. Proper GWAS study design does not only rely on power 
estimation calculation, but also on replication. In the early days of GWAS, the lack of 
replication led to several markers and loci to be erroneously reported. It is now an imperative to 
publication to have replication data for the most promising association results in an 
independent cohort. Given that DRBC is a phenotype rarely measured in clinical studies, 
replication analysis is not readily available, representing the main limitation of our study. We 
calculated our power of association for single variant test based on the non-centrality parameter 
of the chi-squared distribution166 using a custom Rscript. Figure 12 below shows the various 
power curves for N=374 (DRBC sample size in GEN-MOD), and N=1000 (hypothetical 
sample size if additional samples with DRBC measures were added) with  =5 x 10-8 at minor 
allele frequencies of 10%, 25%, and 50%. Based on the power estimation Figure 12 A we have 
70% > power for variants with MAF = 25%, N=374, beta = 0.5, and 90% > power for variants 
with MAF = 25%, N=1000, beta = 0.5 (Figure 12 B). 
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Figure 12. Power Estimation for Association Test of DRBC 
This figure shows the power calculations on y-axis according to different beta (effect sizes) on x-axis with each curves 
representing different allelic frequencies, given that  = 5 x 10-8. In figure A, we assumed that the sample size N = 374 (DRBC 
sample size in GEN-MOD). In figure B, we assumed that the sample size N = 1000 (if we added more samples with DRBC 
values). 
 
2.6.2 Single Variant Testing 
 
Depending on the nature of the phenotype, association testing relies on two types of tests. For 
quantitative traits, the standard is to use a generalized linear model, often an analysis of 
variance (ANOVA) to test whether or not there is a difference in means in any of the genotype 
group for the trait of interest. When the phenotype is dichotomous, a logistic regression or a 
contingency table (i.e., chi-square test) is used.  In a contingency table, we assess the difference 
in genotype frequency between cases and controls. While in the logistic regression the same is 
accomplished estimates of effect size (odds ratio) can be generated, and covariates can be 
added to the model. Test statistics remain the same regardless of the disease mode of 
transmission (additive, dominant, recessive, or multiplicative), however, interpretation of 
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results differ169. For our analysis, we tested SNPs individually in an additive model using linear 
regression given that DRBC is a quantitative trait. 
 
2.6.3 Gene-Based Testing 
Markers with low minor allele frequency are not suitable for single variant test because of the 
reduce power of association170. One approach to overcome this challenge - the one we used 
with DRBC - is to focus on nonsynonymous variation that annotate to the same gene, and then 
testing them using a burden test or a quadratic test171. Given that they test different 
assumptions, we used them both in our study. On one hand burden tests assume that all variants 
are causal and have the same direction of effect (VT172). On the contrary, quadratic tests retain 
power even when variants are not in the same direction or necessarily causal (SKAT 173). 
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2.7 Bioinformatics Analyses 
 
2.7.1 Bioinformatics Software  
 
Table 3. Summary of Bioinformatics Tools 
The table below provides a summary of the tools, source and usage for all the analysis, and quality control steps.  
Software Name Source Usage 
Bedtools Quinlan AR et al.174 
https://github.com/arq5x/bedtools2 
WES QC 
BWA Li H et al.175 
http://maq.sourceforge.net/ 
WES QC 
checkVCF https://github.com/zhanxw/checkVCF Genotype QC 
GATK McKenna A et al176 
https://github.com/broadinstitute/gatk 
WES QC 
Minimac Das S et al165 
http://genome.sph.umich.edu/wiki/Minimac3 
Genotype Imputation 
Picard http://broadinstitute.github.io/picard/ WES QC 
PLINK Chang CC et al177 
https://www.cog-genomics.org/plink2 
Genotype QC & Analysis 
PLINK/SEQ https://atgu.mgh.harvard.edu/plinkseq/ Genotype QC 
Python Custom script: https://github.com/yilboudo GWAS Analysis/WES Analysis 
R Custom script: https://github.com/yilboudo GWAS Analysis/WES Analysis 
Raremetals Liu D.J et al178 
http://genome.sph.umich.edu/wiki/RareMETALS 
Genotype Association Testing 
Rvtest Zhang X et al179 
http://zhanxw.github.io/rvtests/ 
Genotype Association Testing 
SHAPEIT 
 
Delaneau O et al180-182 
https://shapeit.fr/ 
Genotype Imputation 
vcflib https://github.com/vcflib/vcflib#vcflib WES Analysis 
VCFtools http://vcftools.sourceforge.net/ Genotype QC 
VEP McKenna et al176 
http://www.ensembl.org/info/docs/tools/vep/ 
Variant Annotation 
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2.7.2 Genotyping QC and Imputation 
All the individuals were genotyped on the Illumina Infinium HumanOmni2.5Exome-8v1.1 
array. PLINK v1.07 was used to remove poorly genotyped variants and samples. Relatedness 
and duplicate samples were assessed through identity-by-descent calculation (IBD). The 
following parameters were used:   --geno, --mind, --hardy, --maf, --check-sex, --indep 50 5 2, --
IBD, --genome. Population stratification was calculated using PLINKv1.07’s --cluster --mds-
plot 10 with HapMap399 as a reference. The files were converted to variant call format file 
(VCF) with PLINK/SEQ and inspected for strand alignment issues using checkVCF package. 
After splitting the VCF file by chromosomes with vcftools v0.1.11, we phased and imputed 
each file with SHAPEITv2.790 and Minimac3 (v1.0.11) against 1000 Genome phase 3 
haplotypes (version 5) as the reference panel. Subsequently each VCF file was then filtered out 
with a custom python script to include variant with r2 > 0.3.   
 
2.7.3 GWAS Analysis, Prioritization, and VEP annotation  
We derived the association summary statistics for our GWAS using RVTests (v.20140416)179 
with default options, correcting for age, sex and the first 10 principal components. A custom 
python script was used to select variants falling within enhancer regions183,184. Variants 
annotation was performed with VEP default script, and afterward aggregated per gene symbol 
and allelic frequency. Additionally, a Python script was used to distinguish nonsynonymous 
variants with the following consequences: splice_acceptor, splice_donor_variant, stop_gained, 
frameshit_variant, stop_lost, start_lost, protein_altering_variant, missense_variant, 
coding_sequence_variant. We then derived the association summary statistics with 
rareMETALS(v.6.3)178. Identification of proxy variants with LD > 0.8 in the 1000 Genomes 
European population was performed with PLINK v1.09. The following parameters were used: -
-r2, --ld-snp-list, --ld-window-kb 1000, --ld-window 99999, --ld-window-r2 0.8.  
 
2.7.4 Whole-Exome Sequencing Analysis  
We aligned the reads to the human reference genome (version GRCh37/hg19) with BWA 
default parameters. Thus generating sequence alignment map files (SAM) which we merged 
into a single file. Duplicates were marked and removed with Picard with a validation stringency 
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set to lenient. With GATK default parameter, we then proceeded to define intervals to target for 
local realignment. We then performed the local realignment of reads around indels, fixing mate 
pair information. Again, with default options recalibration and realignment steps were also 
carried out with GATK, while for the depth of coverage we set omitBase to true, and minimum 
mapping quality (mmq) and minimum mapping quality to 9. Gene coverage was calculated at -
ct 1 -ct 5 -ct 10 -ct 20 -ct 30. Finally, variant calling was performed with the same tool, using 
default parameters, and then annotated with VEP. Before converting the numerical 
representation of genotypes provided by the GT field in VCF files to a human-readable 
genotype format with vcflib’s option vcfgenotypes all the variants were sorted. Keeping only 
those annotated as nonsynonymous, and with a gene symbol corresponding to our candidate 
genes. We later used a custom python script to identify individuals carrying a mutation. The 
subset of SNPs identified was reannotated with VEP this time querying RefSeq transcripts, 
gene symbol identifiers, exome aggregation consortium (ExAC) allele frequencies, SIFT and 
PolyPhen prediction and score. Finally, each variant was assigned a score for each 
hematological trait analyzed. This was accomplished with a python script that computed the 
average for a hematological trait across individuals carrying the mutation. 
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3. Genome-wide Association Study of Erythrocyte Density in 
Sickle Cell Disease Patients 
 
3.1 Author Contribution 
This article is in preparation and meant to be published in the American Journal of 
Hematology. Yann Ilboudo and Guillaume Lettre conceived and designed the statistical and 
bioinformatics experiments. Yann Ilboudo performed the statistical and bioinformatics 
experiments. Seth L. Alper, Pablo Bartolucci, Carlo Brugnara, Frederic Galactéros, and Alicia 
Rivera contributed DNA samples, clinical information, and expert knowledge. Yann Ilboudo 
and Guillaume Lettre analyzed the results, and wrote the manuscript with contributions from all 
authors. Josepha-Clara Sedzro and Marie Trudel performed mouse matings, genotyping and 
isolation of bone marrow cells. 
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3.3 ABSTRACT 
 
Deoxy-hemoglobin S polymerization into rigid fibers is the direct cause of the clinical sequelae 
observed in sickle cell disease (SCD) patients. The rate of polymerization of deoxygenated 
sickle hemoglobin is determined primarily by intracellular hemoglobin concentration, itself 
dependent on the amount of sickle hemoglobin and on red blood cell (RBC) volume. Dense, 
dehydrated RBC are observed in SCD patients, and their number correlates with hemolytic 
parameters and complications such as renal dysfunction, leg ulcers and priapism. In order to 
identify new genes and biological pathways involved in RBC hydration in SCD, we performed 
the first genome-wide association study for dense RBC (DRBC) in 374 homozygous SCD 
patients. We did not find genome-wide significant results among the 31 million DNA sequence 
variants tested, indicating that variants that modulate DRBC have modest-to-weak effects. A 
secondary analysis demonstrated nominal association of a variant associated with mean 
corpuscular hemoglobin concentration in non-anemic individuals with DRBC in SCD patients 
(P=0.003). This intronic variant controls the expression of ATP2B4, the main calcium pump in 
erythrocytes. We showed that Atp2b4 is not differentially expressed in the bone marrow of 
SCD mice when compared to control mice. Our study highlights ATP2B4 as a promising target 
to modulate RBC hydration in SCD patients. 
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3.4 INTRODUCTION 
 
Sickle cell disease (SCD) is one of the most common monogenic diseases in the world. It is caused 
by a single mutation in the gene that encodes the beta-chain of hemoglobin. Despite this genetic 
homogeneity, SCD patients are characterized by extreme clinical heterogeneity, ranging in 
presentation from benign mild anemia to devastating cerebrovascular events. Studies of the natural 
history of this blood disorder have improved clinical care such that most SCD patients in North 
America and Europe can now expect to reach middle age. Despite this progress, the life expectancy 
and quality-of-life of SCD patients is reduced, treatment options remain limited, and no widely 
accessible curative therapy is available. Moreover, universal genetic screening and improved care 
for SCD have been slow to reach the sub-Saharan region in which resides the vast majority of SCD 
patients. 
 
Results of seminal observational, epidemiological, biochemical, and genetic experiments have led to 
the emergence of fetal hemoglobin (HbF) as a key genetic modifier of severity in SCD185. The 
beneficial effects of hydroxyurea (HU), the only drug currently approved to treat SCD, are mediated 
in part by increasing HbF production. Dense, dehydrated erythrocytes are a hallmark of SCD 
patients, and red blood cell density (DRBC) has been investigated as a potential modifier of patient-
to-patient clinical variability in SCD. Patients with elevated numbers of dense erythrocytes are 
expected to have clinical courses of greater severity, because the intracellular concentration of sickle 
hemoglobin (HbS) influences its rate of polymerization after deoxygenation139. Indeed, a study 
carried out in ~500 SCD patients showed that higher DRBC was associated with increased risk of 
leg ulcer, priapism, and renal dysfunction144. Interestingly, DRBC is only partially correlated with 
HbF, suggesting that therapeutic modulation of DRBC could further reduce complications when 
combined with HbF-stimulating agents such as HU.  
 
Several ion transporters and channels can control directly or indirectly RBC hydration (and thus 
density)186. Senicapoc, a selective inhibitor of the calcium-activated potassium Gardos channel, was 
shown in a mouse model of SCD to reduce the number of DRBC187. A phase III clinical trial of 
senicapoc in SCD patients similarly decreased the number of dense red blood cells, but failed to 
reduce the number of painful vaso-occlusive crises150. Strong interest nonetheless persists in the 
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pursuit of identifying novel drug targets, inhibition of which would selectively re-hydrate 
erythrocytes in SCD patients. Evidence of the pathologic importance of dehydration in SCD 
erythrocytes continues to accumulate188. Human genetics can provide an unbiased approach to 
discover the role of proteins and biological pathways in RBC hydration. In this article, we describe 
results from the first genome-wide association study (GWAS) to identify DNA sequence variants 
associated with DRBC in SCD patients. 
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3.5 METHODS 
 
3.5.1 Ethics Statement 
Informed consent was obtained for all participants in accordance with the Declaration of 
Helsinki. This project was also reviewed and approved by the Montreal Heart Institute Ethics 
Committee and the different recruiting centers.  
 
3.5.2 Samples and DNA Genotyping 
The GEN-MOD study, a cohort of sickle cell disease (SCD) homozygous patients recruited in 
Paris, France, has been described elsewhere144. 408 GEN-MOD participants, for whom red 
blood cell density (DRBC) was measured at baseline using the phthalate density-distribution 
technique, were available for our genetic investigation. The DNA of the GEN-MOD 
participants was genotyped on the Illumina Infinium HumanOmni2.5Exome-8v1.1 array at the 
Montreal Heart Institute Pharmacogenomics Center. We used PLINK154 and other custom 
scripts to control the quality of the genotyping dataset: we excluded samples and markers with 
genotyping success rate <95%, markers out of Hardy-Weinberg Equilibrium (P<1x10-7) and 
markers with extreme (high or low) heterozygosity. We performed multidimensional scaling 
(MDS) in PLINK, anchoring these results on projections obtained using reference populations 
from the 1000 Genomes Project, to detect and remove (after visual inspection) population 
outliers. The Cooperative Study of Sickle Cell Disease (CSSCD) has been described 
extensively elsewhere189-191. Genome-wide genotype data generated with the Illumina 
Human610-Quad array was available for 1,279 CSSCD participants. We conducted genotype 
imputation using Minimac3 (v1.0.11)165 and reference haplotypes from phase 3 of the 1000 
Genomes Project. We restricted association testing to markers with an imputation r2  >0.3. 
 
3.5.3 Statistical analyses 
The descriptive statistics of the participants analyzed in this study are presented in Table 1. 
Continuous phenotypes (DRBC and mean corpuscular hemoglobin concentration (MCHC)) 
were adjusted for sex and age, and the residuals were normalized using inverse normal 
transformation. Because low MCHC can be confounded by the thalassemia trait, we excluded 
from the analyses participants with α-thalassemia or a mean corpuscular hemoglobin (MCH) 
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<26 pg. We used linear regression for association testing between single variants and 
continuous traits, as implemented in RVtests (v.20140416)179. We used Sequence Kernel 
Association Test (SKAT)173 and Variable Threshold (VT)172 for our gene-based testing using 
rareMETALS(v.6.3)178. For gene-based testing, we focused our analysis on genotyped variants 
with minor allele frequency (MAF) <5%. We ran two sets of gene-based analyses: broad set 
(missense, nonsense, splice-site, frameshift and stop codon) and strict set (all of the above 
except missense variants). All genetic association analyses presented in this study were 
adjusted for the ten first principal components. Furthermore, we applied a genomic control 
correction to the DRBC GWAS results. 
 
We defined genome-wide significance as α=5x10-8 and α=2.5x10-6 for single-variant and gene-
based tests, respectively. In the post-hoc prioritization analyses (see below), we considered 
12,360 erythroid enhancers (α=4x10-6 after Bonferroni correction) or expression quantitative 
trait loci (eQTL) for 66 candidate genes (α=8x10-4 after Bonferroni correction). For the 84 
variants previously associated with MCHC by GWAS, and their linkage disequilibrium (LD) 
proxies, we highlighted variants with nominal significance (α=0.05) given the strong prior 
probability of these loci contributing to RBC hydration. 
 
3.5.4 Genetic and functional prioritization of genetic variants 
Given the limited statistical power offered by our sample size, we sought to prioritize variants 
using independent genetic and functional genomic information. In GEN-MOD, DRBC is 
strongly correlated with MCHC (Pearson’s r=0.63, P=7x10-41, Supplementary Figure 1). 
Although MCHC is not a perfect proxy for DRBC, variants associated with RBC dehydration 
are expected to result in increased MCHC. Since hemoglobin concentration is one of the major 
factors influencing sickle hemoglobin (HbS) polymerization,139 we tested the association of the 
top DRBC variants (PDRBC <1x10
-6) for association with MCHC in GEN-MOD and the 
CSSCD. We also tested whether the variants associated with MCHC in a large genome-wide 
association study (GWAS) of European-ancestry non-anemic individuals107 are associated with 
DRBC in SCD participants from GEN-MOD. For this lookup, we considered not only the 
sentinel MCHC GWAS variants, but also all variants in strong LD (r2>0.8) in European 
populations from the 1000 Genomes Project. 
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We also prioritized variants that map to erythroid enhancers defined using DNAse I 
hypersentive sites and histone tail modifications183. Finally, we queried the GTEx database192 
to retrieve eQTL for 66 candidate genes. These genes were pre-selected based on their known 
and suspected roles in erythrocyte hydration. Supplementary Table 1 lists these candidate 
genes and rationales for their inclusion in the study.  
 
3.5.5 RNA extraction and qPCR 
The protocols for in vivo mouse experiments were reviewed and approved by the IRCM 
Animal Care Committee (ACC #2014-27), which follow the regulations and requirements of 
the Canadian Council on Animal Care (CACC). Transgenic SAD sickle cell disease mice have 
been backcrossed for 49th generation on C57Bl/6J inbred mouse and were genotyped by 
hemoglobin analysis for the presence of human globin chains193. Adult male SAD (n=3) and 
control (n=3) bone marrow cells were obtained from femur flushed with PBS and 1% fetal 
bovine serum. Bone marrow cells were then centrifuged at 1400rpm for 5 minutes and flash 
frozen on liquid nitrogen.  
 
We extracted RNA from mice bone marrow using the RNeasy Plus mini kit from Qiagen. RNA 
quality and concentration were measured by Agilent RNA 6000 Nano II assays (Agilent 
Technologies) on an Agilent 2100 Bioanalyzer and purity was assessed by Nanodrop.  We 
reverse transcribed 1g of total RNA using random primers and the MultiScribe Reverse 
Transcriptase from Applied Biosystems. We performed qPCR analysis using Platinum SYBR 
Green qPCR SuperMix-UDG (Life Technologies) on the CFX384 (Biorad) with the following 
thermal profile: 10 minutes at 95°C, and 40 cycles of: 30 seconds at 95°C, 30 seconds at 55°C 
and 45 seconds at 72°C following by a melt curve. Expression levels were measured and 
normalized in relation to the expression levels of the reference gene hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) and ribosomal S16 using the ΔΔCq method194 and the 
geNorm software.  We obtained a M value of 0.871.  For Atp2b4, we used Quantitect primer 
assay from Qiagen (QT00252532).  The primer sequences are: S16 forward (5’-
AGGAGCGATTTGCTGGTGTGG-3’) and reverse (5’-GCTACCAGGGCCTTTGAGATG-
3’); Hprt forward (5’-CAGCGTCGTGATTAGCGATG-3’) and reverse (5’-
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CAGAGGGCCACAATGTGATGG-3’).  
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3.6 RESULTS 
 
3.6.1 Genome-wide association study of red blood cell density 
 
After quality-control and genotype imputation, we performed a genome-wide association study 
(GWAS) between ~31 million DNA sequence variants and red blood cell density (DRBC) in 
374 sickle cell disease (SCD) patients from the GEN-MOD cohort (Table 1). Although our 
single variant analysis was adjusted using principal components, we noted a modest inflation of 
the test statistics (λGC=1.1, Figure 1). For this reason, we corrected the test statistics using 
genomic controls. Table 2 presents results for loci and associated variants with PDRBC <5x10
-6. 
Gene-based testing focused on directly genotyped coding variants with minor allele frequency 
(MAF) <5% identified no significant association with DRBC. 
 
The gold standard validation of genetic association studies requires replication of the initially 
observed associations for the same phenotype and variant in an independent cohort. 
Unfortunately, we are unaware of any SCD cohorts of sufficient size to replicate our DRBC 
genetic results. For this reason, we explored the use of mean corpuscular hemoglobin 
concentration (MCHC) as a surrogate phenotype. DRBC and MCHC are highly correlated in 
SCD patients (Supplementary Figure 1), and high DRBC and MCHC each can reflect 
erythrocyte dehydration. Thus, a variant associated with DRBC might be predicted also to 
associate with MCHC. 
 
First, we tested the association between the top variants associated with DRBC in GEN-MOD 
and MCHC in GEN-MOD. As expected for two correlated traits tested in the same individuals, 
several variants are associated with both DRBC and MCHC in GEN-MOD (Table 2). As an 
independent validation step, we performed the MCHC analysis in the Cooperative Study of 
Sickle Cell Disease (CSSCD). After excluding participants with α-thalassemia, which may 
independently affect MCHC, we identified 584 CSSCD participants with baseline MCHC and 
genotype data available. Only one of the 15 variants tested with PDRBC <5x10
-6 in GEN-MOD 
had a PMCHC <0.05 and consistent direction of effect in the CSSCD: this variant, rs59264502, is 
common (MAF=46%) and intergenic (Table 2).   
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3.6.2 Variant prioritization 
 
We implemented three strategies to increase the probability of finding robust genetic 
associations with DRBC. First, we considered variants mapping to erythroid enhancers, as 
defined by DNAse I hypersensitive sites and histone modifications183. Among the 12,360 
regulatory elements tested, we found no variants more strongly associated with DRBC than 
would be expected by chance (Figure 1). Second, we retrieved from the GTEx resource192 
expression quantitative trait loci (eQTL) for 66 candidate genes, selected because they encode 
proteins with direct or indirect effects on red blood cell hydration (Supplementary Table 1). 
Three of these genes had eQTLs that were also associated with DRBC in SCD patients from 
GEN-MOD (at PDRBC <8x10
-4, Bonferroni correction for 66 genes), although none were 
significantly associated with MCHC in the CSSCD (Table 2). These three promising variants 
control the expression of the Mg2+ transporter SLC41A3, cytoskeletal protein SPTB (beta 
spectrin), and mechanosensitive cation channel PIEZO1. 
 
Our final strategy to prioritize variants was to exploit the physiological link between DRBC 
and MCHC. We reasoned that some variants previously associated with MCHC by GWAS 
could also influence DRBC. A recent meta-analysis carried out in 173,480 participants of 
European ancestry identified 84 DNA sequence variants robustly associated with MCHC107. To 
accommodate ethnicity difference, we retrieved DRBC results for these 84 variants as well as 
for all variants in strong linkage disequilibrium (LD, r2>0.8 in European-ancestry individuals 
from the 1000 Genomes Project). This query highlighted eight variants with PDRBC <0.05 
(Table 3). 
 
One of these eight variants, rs1203972, is located near the α-globin locus on chromosome 16. 
This is promising since the presence of α-thalassemia is associated with fewer DRBC144, 
although it is unknown whether this specific SNP is in LD with an α-thalassemia mutation. The 
most common cause of α-thalassemia in individuals of African ancestry is a 3.7-kb deletion 
that encompasses one of the genes (HBA2) encoding the α-chain of hemoglobin. Analyses of 
whole-genome sequence data from African populations in the 1000 Genomes Project 
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showed this deletion is in LD with rs13335629195. However, rs1203972 and rs13335629 are not 
in LD in GEN-MOD (r2=0.02), nor is rs13335629 associated with DRBC (PDRBC=0.24).  
 
3.6.3 ATP2B4 and DRBC in SCD patients 
 
The second interesting result arising from this analysis of MCHC-associated SNPs in the 
DRBC GWAS data is an intronic SNP at the ATP2B4 locus. ATP2B4, also known as PMCA4, 
encodes the main calcium pump of erythrocytes. We recently showed that this SNP, 
rs10751450, strongly associated with MCHC in European populations107 and with malaria 
susceptibility in African populations196, is an erythroid-specific eQTL for ATP2B4 (Samuel 
Lessard and G.L., unpublished). We compared Atp2b4 expression in bone marrow of normal 
mice and SAD mice193, a well-established mouse model of sickle cell disease (Figure 2). 
Atp2b4 was not differentially expressed (t-test P=0.68). Next, we tested a potential differential 
impact on red cell volume in normal and SAD mice of PMCA4 inhibition by 
aurintricarboxylicacid (ATA). 
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3.7 DISCUSSION 
 
By genotyping 403 GEN-MOD individuals, we ran the first genome-wide scan of DRBC. We 
didn’t identify new genomic loci, whether when testing variants one at time, or when testing 
them as a collection in a gene. Notwithstanding the lack of samples for replication, we 
leveraged the strong connection between DRBC and MCHC and investigated the association of 
MCHC in GEN-MOD and CSSCD. This analysis yielded only one significant DNA sequence 
variant in both cohorts with matching effect size directions, therefore constituting our only 
pseudoreplication of DRBC variants.  
 
To further elucidate genetic modulator of DRBC, we prioritized variants evaluating erythroid 
specific enhancers, and eQTLs in candidate genes. Additionally, we cross-referenced DRBC 
associations results in GEN-MOD to those found in a large meta-analysis of non-anemic 
Europeans for MCHC. We note that our candidate gene approach, and cross-reference analysis 
provided promising results implicating mutations in genes previously reported to have a 
functional impact on dense red cell physiology. The exact impact of these variations in SCD 
remains suggestive, awaiting replication and functional characterization as we did with 
PMCA4. 
 
The genome-wide association of DRBC can provide a window into a better comprehension of 
SCD severity, and broadly the osmotic regulation in red blood cell. In addition to the need for 
molecular characterization of our promising findings, the need for additional samples to 
unearth DRBC loci are current limitations of this study. From a clinical standpoint, while the 
Senicapoc150 trial failed, it showed that targeting red cell transporter channels can effectively 
rehydrate red blood cells and reduce the rate of some SCD-related complications. In the same 
line of thought, identifying DRBC susceptibility loci can inform us on additional strategies to 
rehydrate red blood cell in SCD patients with the goal of eliminating all complications.  
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Table 1. Descriptive statistics of the GEN-MOD and CSSCD sickle cell disease participants 
analyzed in this study. For continuous variables, we provide the mean ± standard deviation and 
the number of participants with available data. NA, not available 
Phenotype GEN-MOD (N=408) CSSCD (N=1279) 
Males/females 185 / 223 616 / 663 
Age, years  30 ± 9  13 ± 12 
DRBC, % 13.1 ± 8.6 NA 
MCHC, g/dL 34.5 ± 1.8 34.6 ± 1.16 
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Table 2. Top single variant association results with red blood cell density (DRBC) in 374 participants from GEN-MOD. We 
included in this table variants with PDRBC <5x10
-6 or variants that are expression quantitative trait loci (eQTL) for candidate genes in 
GTEx and have a PDRBC <8x10
-4 (Methods). Chr:Pos, genomic coordinates on build hg19; REF/ALT, reference and alternate alleles; 
AF, frequency of the alternate allele; BETA/SE, effect size (for the alternate allele) and standard error in standard deviation units. 
rsID Chr:Pos REF/ALT GEN-MOD, DRBC (N=374) 
GEN-MOD, MCHC 
(N=317) 
CSSCD, MCHC (N=584) Gene Annotation 
   AF 
BETA 
(SE) 
P-value 
BETA 
(SE) 
P-value AF 
BETA 
(SE) 
P-value   
Top association results 
rs4234795 4:7210802 A/G 0.94 
-0.84 
(0.15) 
1.99x10-7 
-0.46 
(0.17) 
0.0062 0.94 
0.03 
(0.13) 
0.80 SORCS2 intron 
rs9714060 3:195487476 A/G 0.43 
-0.39 
(0.08) 
7.43x10-7 
-0.11 
(0.08) 
0.19 0.44 
-0.01 
(0.07) 
0.93 MUC4 intron 
rs146893001 9:112181617 T/C 0.01 
-2.04 
(0.4) 
1.29x10-6 
-1.33 
(0.6) 
0.028 0.004 
-0.06 
(0.48) 
0.90 PTPN3 intron 
rs7216169 17:5219511 C/T 0.22 
0.45 
(0.09) 
1.36x10-7 
0.25 
(0.1) 
0.0087 0.22 
0.05 
(0.08) 
0.54 RABEP1 intron 
rs543023132 6:155973785 GTTTT/G 0.02 
-1.54 
(0.3) 
1.37x10-6 
-0.68 
(0.36) 
0.061 0.022 
-0.15 
(0.21) 
0.47 - intergenic 
rs144995469 14:57199082 C/T 0.03 
-1.15 
(0.23) 
1.48x10-6 
-0.32 
(0.26) 
0.22 0.033 
0.36 
(0.18) 
0.039 - intergenic 
rs74989317 21:35296139 T/A 0.04 
-0.99 
(0.2) 
1.53x-10-6 
-0.42 
(0.2) 
0.041 0.045 
-0.21 
(0.15) 
0.17 - regulatory 
rs73108077 20:30006859 T/C 0.06 
-0.83 
(0.17) 
1.75x10-6 
-0.22 
(0.2) 
0.27 0.063 
-0.07 
(0.13) 
0.58 DEFB122 downstream 
rs114402357 13:22493635 C/T 0.01 2.03 (0.4) 1.78x10-6 
1.1 
(0.45) 
0.015 0.016 
0.28 
(0.25) 
0.26 - intergenic 
rs77141833 1:159825190 T/C 0.03 
-1.12 
(0.22) 
1.80x10-6 
-0.44 
(0.28) 
0.12 0.032 
0.08 
(0.18) 
0.66 VSIG8 intron 
rs62015549 15:71671418 C/T 0.01 
-2.44 
(0.49) 
1.89x10-6 
-1.07 
(0.73) 
0.15 
0.015 
 
-0.25 
(0.26) 
0.33 THSD4 intron 
rs76513454 1:218861569 G/C 0.01 
-2.17 
(0.43) 
1.97x10-6 
-0.93 
(0.73) 
0.20 NA NA NA - intergenic 
rs139628543 2:239053045 A/C 0.06 
0.75 
(0.15) 
1.99x10-6 
0.22 
(0.17) 
0.19 0.05 
0.08 
(0.14) 
0.59 KLHL30 intron 
             
rs59264502 13:106846272 AT/A 0.46 
0.37 
(0.08) 
2.39x10-6 
0.21 
(0.08) 
0.011 0.47 
0.14 
(0.06) 
0.030 - intergenic 
rs147900370 1:115552925 A/C 0.04 
-0.92 
(0.18) 
2.44x10-6 
-0.35 
(0.21) 
0.090 0.038 
-0.09 
(0.17) 
0.59 - intergenic 
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eQTL for candidate genes 
rs62270871 3:125672365 G/A 0.51 0.33(0.07) 2.60x10-5 
0.14 
(0.08) 
0.11 0.47 
0.02 
(0.07) 
0.71 ALG1L 
intron; eQTL for 
SLC41A3 
rs146977005 14:65305030 G/GA 0.28 
-
0.33(0.09) 
5.5x10-4 
-0.10 
(0.09) 
0.26 0.75 
0.11 
(0.07) 
0.15 SPTB 
intron; eQTL for 
SPTB 
rs8048714 16:88809773 G/C 0.72 -0.3(0.08) 7.3x10-4 
0.08 
(0.1) 
0.45 0.25 
0.14 
(0.07) 
0.056 PIEZO1 
intron; eQTL for 
PIEZO1 
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Table 3. Top association results between variants previously associated with mean corpuscular hemoglobin concentration (MCHC) 
in non-anemic European-ancestry individuals and red blood cell density in 374 sickle cell disease patients. We included in this table 
variants with nominal PDRBC <0.05. Chr:Pos, genomic coordinates on build hg19; REF/ALT, reference and alternate alleles; AF, 
frequency of the alternate allele; BETA/SE, effect size (for the alternate allele) and standard error in standard deviation units. 
rsID Chr:Pos REF/ALT GEN-MOD, DRBC (N=374) Gene Annotation 
   AF BETA (SE) P-value   
rs144514173 1:205246482 TTTTG/T 0.108 0.37 (0.12) 0.0029 TMCC2 downstream 
rs10751450 1:203650945 C/T 0.643 -0.25 (0.08) 0.0031 ATP2B4 intron 
rs148303943 6:16263455 T/C 0.85 -0.32 (0.11) 0.0057 GMPR intron 
rs11421513 6:13901073 G/GT 0.689 -0.23 (0.08) 0.0074 - intergenic 
rs1203972 16:283232 T/C 0.658 -0.22 (0.08) 0.0082 LUC7L upstream 
rs201794926 8:145710909 G/GA 0.491 0.18 (0.07) 0.021 PPP1R16A intron 
rs34514965 19:13071559 T/TG 0.832 0.21 (0.1) 0.043 GADD45GIP1 upstream 
rs5875087 6:26118437 CA/C 0.906 -0.27 (0.13) 0.045 HIST1H2BC intron 
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Figure 1. Distribution of genome-wide association results with red blood cell density (DRBC) 
in 374 sickle cell disease patients. We present results for all imputed markers (pink), markers 
that map to erythroid enhancers (purple), markers that are expression quantitative trait loci 
(eQTL) for 66 candidate genes implicated in red blood cell hydration (brown), and markers 
associated with mean corpuscular hemoglobin concentration (MCHC) from previous genome-
wide association studies (green). The grey area corresponds to the 95% confidence interval. 
λGC, genomic inflation factor. 
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Figure 2. Atp2b4 expression levels in the bone marrow of normal mice (C57) or a mouse 
model of sickle cell disease (SAD). RNA was extracted from both femurs of three C57 and 
three SAD mice. Data show mean ± standard error of the mean. Atp2b4 is not differentially 
expressed between the bone marrow of C57 and SAD mice (t-test P=0.68). 
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Supplementary Figure 1. Correlations (Pearson’s r) between hematological parameters 
corrected for age, and sex in up to 408 patients with sickle cell disease from the GEN-MOD 
cohort. Numbers in blue and red indicate positive and negative correlations, respectively. Cells 
with an “X” are non-significant correlations (P≥0.05).  
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Supplementary Table 1. List of candidate genes with a potential role in red blood cell 
hydration. 
Official Gene Symbol Gene Name Rationale 
ABCB6 
ATP-binding cassette, sub-family B 
(MDR/TAP), member 6 (Langereis blood 
group) 
Mutations in this nominal pyrrole/hemin transporter cause autosomal dominant pseudohyperkalemia 
and can cause hereditary xerocytosis with transient perinatal edema 
ABCG5 
ATP-binding cassette, sub-family G (WHITE), 
member 5 
Mutations in this sterol hemitransporter cause hereditary sitosterolemia with stomatocytosis 
ABCG8 
ATP-binding cassette, sub-family G (WHITE), 
member 8 
Mutations in this sterol hemitransporter cause hereditary sitosterolemia with stomatocytosis 
ANK1 Ankyrin 1, Erythrocytic Ankyrin - LOF mutations are the most common cause of hereditary spherocytosis 
ANO1 
Anoctamin 1, calcium activated chloride 
channel 
ANO1/TMEM16A knockout murine RBC exhibit reduced Ca2+-activated anion current 
ANO6 Anoctamin 6 
Ca2+-activated anion channel with phospholipid flippase activity – Loss-of-function mutations cause 
Scott Syndrome 
ATP1A1 
ATPase, Na+/K+ transporting, alpha 1 
polypeptide 
Na+/K+ -ATPase alpha1 subunit 
ATP1A2 
ATPase, Na+/K+ transporting, alpha 2 
polypeptide 
Na+/K+ -ATPase alpha2 subunit 
ATP1B1 
ATPase, Na+/K+ transporting, beta 1 
polypeptide 
Na+/K+ -ATPase beta1 subunit 
ATP1B2 
ATPase, Na+/K+ transporting, beta 2 
polypeptide 
Na+/K+ -ATPase beta2 subunit 
ATP2B1 
ATPase, Ca2+ transporting, plasma membrane 
1 
PMCA1 is one of the calcium ATPases of the RBC membrane 
ATP2B4 
ATPase, Ca2+ transporting, plasma membrane 
4 
PMCA4 is one of the calcium ATPases of RBC membrane. It inhibited by vanadate; binding to 
maitotoxin elicits cation channel activity 
CACNA1A 
Calcium channel, voltage-dependent, P/Q 
type, alpha 1A subunit 
P/Q-type voltage-gated Ca2+ channel implicated by omega-agatoxin blockade of LPS-stimulated Ca2+ 
entry into RBC 
CR1 
Complement component (3b/4b) receptor 1 
(Knops blood group) 
Complement receptor 1 liganding elevates RBC calcium and triggers phosphorylation cascades 
EPB41 Erythrocyte membrane protein band 4.1 Band 4.1 erythroid isoform - loss-of-function mutations cause elliptocytosis 
EPB42 Erythrocyte membrane protein band 4.2 Band 4.2 LOF mutations cause spherocytosis in Japanese 
FXYD2 
FXYD domain containing ion transport 
regulator 2 
Na+/K+ -ATPase gamma subunit.- also part of or regulator of a renal distal tubular Mg2+  channel 
GRIN1 
Glutamate receptor, ionotropic, N-methyl D-
aspartate 1 
NMDA receptors (NMDAr) have been defined pharmacologically in RBC membrane. Liganding 
elevates Ca2+ and promotes ATP release and can promote shape change. Antagonist memantine is under 
consideration for clinical trial in sickle disease 
GRIN2A 
Glutamate receptor, ionotropic, N-methyl D-
aspartate 2A 
NMDAr subunit 
GRIN2B 
Glutamate receptor, ionotropic, N-methyl D-
aspartate 2B 
NMDAr subunit 
GRIN2 
Glutamate receptor, ionotropic, N-methyl D-
aspartate 2C 
NMDAr subunit 
GRIN2D 
Glutamate receptor, ionotropic, N-methyl D-
aspartate 2D 
NMDAr subunit 
KCNK5 Potassium channel, subfamily K, member 5 Two-pore domain (K2P) potassium channel in RBC proteome 
KCNK6 Potassium channel, subfamily K, member 6 Two-pore domain (K2P) potassium channel in RBC proteome 
KCNN4 
Potassium intermediate/small conductance 
calcium-activated channel, subfamily N, 
member 4 
Gardos Channel KCa3.1, gain-of-function mutations cause hereditary xerocytosis 
KEL Kell blood group, metallo-endopeptidase Unknown function, mutant in neuro-acanthocytosis syndrome 
NOX4 NADPH oxidase 4 Candidate contributor to oxidative damage to RBC membrane 
NOX5 NADPH oxidase Candidate contributor to oxidative damage to RBC membrane 
P2RX7 
Purinergic receptor P2X, ligand-gated ion 
channel, 7 
Deoxygenation releases ATP from normal RBC and (to greater degrees) from sickle RBC, and RBC 
P2X7 may act as both cation channel and ATP permease 
PANX1 Pannexin 1 
Pannexin 1 (homologous connexin gap junction hemichannels) is a pH-gated permease for mid-range 
solutes, including ATP 
PANX2 Pannexin 2 Relative of PANX1 
PANX3 Pannexin 3 Relative of PANX1 
PIEZO1 
Piezo-type mechanosensitive ion channel 
component 1 
Gain-of-function mutations in this mechanosensitive Ca-permeable cation channel cause autosomal 
dominant hereditary xerocytosis 
PIEZO2 
Piezo-type mechanosensitive ion channel 
component 2 
Sensory neuron-predominant homolog of PIEZO1, expression in RBC uncertain 
PKD2 
Polycystic kidney disease 2 (autosomal 
dominant) 
Ca2+ -permeable cation channel, expression in RBC uncertain - otherwise widely expressed as part of 
endoplasmic reticulum Ca release mechanism in addition to plasma membrane location 
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PRDX1 Peroxiredoxin 1 
Redox regulators binding to RBC membrane and likely acting on membrane proteins, including 
transporters and channels 
PRDX2 Peroxiredoxin 2 Relative of PRDX1 
RHAG Rh-associated glycoprotein 
This component of Rh antigen has missense mutations associated with overhydrated stomatocytosis 
with increased RBC cation permeability 
SLC12A4 
Solute carrier family 12 (potassium/chloride 
transporter), member 4 
KCC1; gain-of-function mutation associated with RBC dehydration and sickle disease exacerbation in 
mouse model 
SLC12A6 
Solute carrier family 12 (potassium/chloride 
transporter), member 6 
KCC3; predominant K-Cl cotransporter of murine RBC 
SLC12A7 
Solute carrier family 12 (potassium/chloride 
transporter), member 7 
KCC4 
SLC2A1 
Solute carrier family 2 (facilitated glucose 
transporter), member 1 
Missense mutation of GLUT1 can cause overhydrated stomatocytosis with increased RBC cation 
permeability 
SLC41A1 
Solute carrier family 41 (magnesium 
transporter), member 1 
Candidate Na+/Mg+ exchanger - intracell Mg regulates KCC activity 
SLC41A2 
Solute carrier family 41 (magnesium 
transporter), member 2 
Candidate Na+/Mg+ exchanger 
SLC41A3 Solute carrier family 41, member 3 Candidate Na+/Mg+ exchanger 
SLC4A1 
Solute carrier family 4 (anion exchanger), 
member 1 (Diego blood group) 
Band 3 is the major intrinsic protein of RBC - Overhydrated stomatocytosis mutations associated with 
increased RBC cation leak 
SPTA1 Spectrin, alpha, erythrocytic Alpha-spectrin - LOF mutations cause herededitary spherocytosis 
SPTB Spectrin, beta, erythrocytic Beta-spectrin - LOF mutations cause hereditary spherocytosis 
STOM Stomatin 
Stomatin (STOM) protein deficiency is associated with some forms of hereditary spherocytosis; but 
STOM knock out without RBC phenotype in mouse. 
STOML1 Stomatin (EPB72)-like 1 STOM-related protein 
STOML2 Stomatin (EPB72)-like 2 STOM-related protein 
STOML3 Stomatin (EPB72)-like 3 Stomatin-related protein whose oligomerization modulates PIEZO2 activity 
TRPC1 
Transient receptor potential cation channel, 
subfamily C, member 1 
In murine RBC, one of the Ca2+entry pathways 
TRPC3 
Transient receptor potential cation channel, 
subfamily C, member 3 
Hetero-oligomerizes with TRPC6 
TRPC6 
Transient receptor potential cation channel, 
subfamily C, member 6 
In murine RBC, one of the RBC Ca2+entry pathways 
TRPM2 
Transient receptor potential cation channel, 
subfamily M, member 2 
Mg2+ -permeable cation chanzyme expressed widely 
TRPM4 
Transient receptor potential cation channel, 
subfamily M, member 4 
Transient receptor potential family cation channel, RBC expression uncertain 
TRPM7 
Transient receptor potential cation channel, 
subfamily M, member 7 
Mg2+ cation permease/chanzyme 
TRPV1 
Transient receptor potential cation channel, 
subfamily V, member 1 
Transient receptor potential family cation channel activated by vanilloids, expression in RBC uncertain 
TRPV4 
Transient receptor potential cation channel, 
subfamily V, member 4 
Transient receptor potential family cation channel activated by hypotonic swelling, expression in RBC 
uncertain 
TRPV5 
Transient receptor potential cation channel, 
subfamily V, member 5 
Ca-selective channel of distal convoluted tubule - not known to be expressed in RBC 
TRPV6 
Transient receptor potential cation channel, 
subfamily V, member 6 
Ca-selective channel of enterocytes - not known to be expressed in RBC 
TUSC3 Tumor suppressor candidate 3 Candidate Mg transporter of unknown mechanism and RBC expression 
VDAC1 Voltage-dependent anion channel 1 
Nonspecific large-pore channel of mitochondrial inner membrane has also been reported in RBC 
membrane 
VDAC2 Voltage-dependent anion channel 2 VDAC1 homolog 
VDAC3 Voltage-dependent anion channel 3 VDAC1 homolog 
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4. Whole-Exome Sequencing of Sixty-Four Patients with Sickle 
Cell Disease 
 
4.1. Motivation 
As mentioned earlier, manifestations of SCD-related complications become noticeable as soon 
as the protective effects of HbF dwindle. Whole-exome sequencing is a powerful method to 
identify rare coding mutations with moderate-to-large effect size, and to personalize therapies 
for patients197,198. We present a report of whole-exome sequencing in 64 patients from the 
GEN-MOD cohort, connecting mutations in candidate genes to SCD-related complications. 
 
4.2. Methods 
Cohort selection. 64 homozygous (S/S) patients were selected from the GEN-MOD cohort144 
at the top 10% and bottom 10% of HbF distribution from another study on HbF.  
 
Variant Annotation and Selection. We annotated all the variants, using Variant Effect Predictor 
(VEP) from Ensembl199, querying allele frequency across all ethnicities, and for the 
African/African American (AFR) population from Exome Aggregation Consortium (ExAC)200. 
Additionally, we included protein prediction and scores from SIFT and PolyPhen201,202 which 
assess the probable impact of a nonsynonymous mutation on the protein function. We then 
selected autosomal variants annotated as nonsynonymous and which gene symbol 
corresponded to a subset of our candidate gene (Supplementary Table1).  
 
Variant Scoring and Association to DRBC. To link the variants to the hematological traits, we 
calculated the average HBG, HbF, Retic, HCT, WBC, MCV, MCH, and MCHC across 
individuals carrying a mutation. We did the same for DRBC which we inversed normal 
transformed correcting for age and sex. 
 
Targeted Exon Capture and Whole Exome Sequencing. Targeted regions of genomic DNA 
were captured using NimbleGen SeqCap EZxome V3.0 solution-based capture system as 
specified by the company’s protocol. This was performed at the Montreal Heart Institute, 
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pharmacogenomics center. The captured, purified, and amplified libraries targeting the exomes 
from SCD patients were sequenced on Illumina HiSeq with paired-end sequencing at 100bp 
read length. 
Exome Sequence QC Analysis. Sequencing reads were aligned to the human genome (version 
hg 19/build 37) using BWA mem 0.5.9a software175. We followed the most current best 
practices recommendations that exist for GATK176,203 to complete variant calling, recalibration, 
and to remove duplicates.  
 
4.3. Results and Discussion 
 
4.3.1 Cohort description 
Our analysis included individuals with extreme DRBC values (Figure 14). However, 9 out of 
64 selected patients had missing DRBC measures. Although they remained in our exome 
sequencing analysis, they were not used when computing the hematological traits’ averages 
across individuals per variant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Whole-Exome Sequencing Dense Red Blood Cell 
Distribution in GEN-MOD 
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4.3.2 Data Mining Variant Annotation and Correlation 
Top DRBC z-score. Post variant annotation, we prioritized 297 nonsynonymous variants that 
map to our candidate genes (Supplementary Table1) for further analysis. We visually 
correlated all these variants against the nine hematological traits mentioned earlier (Figure 15). 
The purpose of this representation is to single out mutations carried by individuals that could 
explain the severity of the disease. Overall, Figure 15 shows that the more the variants are 
shared amongst all the individuals the more the DRBC z-score is 0. Meaning that several of the 
shared mutations don’t explain the disease severity. However, as we move towards increasing 
or decreasing DRBC z-score values we can see that hematological traits increase or decrease 
depending on the correlation between DRBC and the blood trait (Supplementay Figure 1). 
The approach is most evident for MCV, MCHC, HCT and RETIC, as opposed to the other 
traits. 
Focusing on variants with DRBC z-score > 1, we found 7 rare DNA sequences (Table 4), that 
could explain the role of dense cells in SCD severity. A patient with a history of leg ulcers, 
priapism, gallbladder removal, and sceptic necrosis was identified with two mutations in 
different genes. One of them in ATP1B2, a heterozygous replacement of A to a G 
(rs531342420) substituting a Gln (CAG) for an Arg(CGG) amino acid at the 108 position. The 
other mutation predicted to be damaging by both SIFT and Polyphen, replaced of a G for an A 
in SPTB, changing an Arg (CGG) to Trp (TGG) amino acid at the 44 position. The patient in 
which these variations were uncovered has the highest DRBC measure (37%) of the analyzed 
cohort. According to study by Bartolucci et al144, denser erythrocyte lead to an increased 
incidence of SCD-related pathology, particularly skin ulcer, priapism, and renal dysfunction. 
Plus, although the in silico prediction of the ATP1B2 missense change is non-pathogenic, the 
gene is also known as AMOG (Ca2+-dependent adhesion molecule of glia) expressed 
abundantly in the brain and the retina. The protein binds to retinoschisin, a retinal degeneration 
gene for X-linked human juvenile retinoschisis.  
Another patient with a medical history of stage 1 or 2 retinopathy, and priapism was identified 
with two rare mutations predicted to be deleterious by both prediction algorithms (Table 4), in 
SLC12A7 and SPTA1. The mutant allele is found in the solute carrier KCC4 gene. It’s an 
heterozygous replacement of G to an A (rs146681871). It changes Ser (TCG) to Leu (TTG) at 
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the 84 position. The other mutant allele is found in the protein that encodes the spectrin alpha, 
erythrocytic 1, and substitutes an A for a T (rs146681871), changing Leu (CTG) to Gln (CAG) 
at the 1565 position.  
Additionally, three rare DNA sequence variations were identified in SLC12A7 (rs139369204, 
COSM4127004), TRMP7 (rs202245737), and ABCB6 (rs113159519) genes in the same 
individual with a history of gall bladder removal and stage 1 or 2 of retinopathy. None of the 
previously mentioned mutations were predicted to be detrimental by our prediction algorithms. 
Finally, the same SNP (rs34246477) in PIEZO1, the mammalian mechanosensory protein, was 
predicted to be deleterious by SIFT but benign by PolyPhen and had two different carriers. 
 
Other Noteworthy Mutations 
We shed light on four previously reported pathogenic mutations associated with hereditary 
spherocytosis (HS). In fact, mining the patient’s medical history, revealed a prior of a 
combination of at least two of the following five complications; leg ulcer, gall blader removal, 
retinopathy, priapism or aseptic necrosis. Two SNPs in ANK1 gene known as the ankyrin 
Brüggen mutation (rs2304877, COSM3982542, COSM3982541), and other one known as the 
Tubarao mutation (rs35213384)204,205. Additionally, two others missense mutations known as 
the Montefiore (CM930673, rs45562031, BGMUT_178) and the Tuscaloosa (CM920621, 
rs28931583)206-208 were in SLC41A gene. Finally, a SNP (rs145343957) in PKD2 the autosomal 
dominant polycystic kidney disease gene was found in an individual who exhibited four of the 
complications mentioned earlier. By and large, these mutations are linked to blood disorder 
other than SCD, they affect red cell membrane deformability, so these results could potentially 
highlight the concomitance of SCD and HS in GEN-MOD a phenomena previously reported in 
SCD patients209.  
 
Future Directions 
Sequencing additional individuals with extreme DRBC values will help confirm our current 
findings, and unearth additional findings. Although, functional experiments need to be 
undertaken to ascertain the causal link between these DNA sequence variations and their 
impact on SCD complications, and on red cell density, more prioritization of variants through 
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functional annotation can be undertaken. Based on the inconsistencies of SIFT and PolyPhen 
algorithms210, it would be of interest to lookup additional severity prediction tools (e.i., 
FATHMM-MKL, MutationTaster2, Mutation Assessor, PROVEAN, CADD) and then identify 
their consensus, and their differences in term of prediction210. Finally, as we sequence the 
exome of more individuals we will gain enough statistical power to run association testing on 
this dataset.  
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Figure 15. Visual Correlation of the z-score of Dense Red Blood Cell to Hematological Traits 
Variants color-coded based on gradient of the average hematological traits. The x-axis represents the number of individuals with carrying a 
mutation and the y-axis shows the average z-score DRBC for each mutation.   
  
Table 4. Top DRBC Missense Mutations From WES 
The table provides the top DRBC missense mutation: SNP: The position of the mutation in the genome; N Carriers: number of individuals carrying a mutation; SNP, Avg. zDRBC: 
average z-score across individuals carrying a mutation; Avg. DRBC, average DRBC across individuals carrying a mutation; REF, the allele from the reference human genome; ALT, the 
non-reference allele observed in the sample; Gene Symbol, symbol of the protein sequence; Existing Variation, rsID, SIFT, prediction algorithm determines whether an amino acid 
substitution affects protein function; PolyPhen, prediction algorithm determines whether an amino acid substitution affects protein function; Annotation Details, details on the amino acid 
substitution and position; ExAC AFR MAF, minor allele frequency for the African/African American populations from the Exome Aggregation Consortium.  
 
SNP 
N  
Carriers 
Avg. 
zDRBC 
Avg. 
DRBC REF/ALT 
Gene 
Symbol 
Existing 
variation SIFT/PolyPhen Annotation Details 
ExAC 
AFR MAF 
chr17:7557240 1 2.36 37 A/G ATP1B2 rs531342420 tolerated(0.26)/benign(0.004) Gln108Arg [exon3] 
T:0, 
G:9.6e-05 
chr14:65289683 1 2.36 37 G/A SPTB - deleterious(0)/probably_damaging(1) Arg44Trp  [exon1] - 
chr16:88792725 2 1.52 24 G/A PIEZO1 rs34246477 deleterious(0.04)/benign(0.079) Ala1312Val  [exon27] A:0.011 
chr15:50884381 1 1.52 24 A/G TRPM7 rs202245737 
tolerated_low_confidence(0.08)/possibly
_damaging(0.447) Ser1351Pro  [exon26] G:0.0013 
chr2:220081152 1 1.52 24 G/C ABCB6 rs113159519 tolerated(0.19)/benign(0.005) Leu302Val  [exon4] C:0.0011 
chr5:1065523 1 1.52 24 C/T SLC12A7 rs139369204 tolerated(0.1)/probably_damaging(0.991) Arg771Gln [exon18] T:0.00070 
chr5:1093739 1 1.92 25 G/A SLC12A7 rs146681871 
deleterious(0.01)/probably_damaging(0.9
99) Ser84Leu [exon3] A:0.0020 
chr1:158589121 1 1.92 25 G/A SPTA1  deleterious(0.01)/benign(0.212) Arg2141Trp  [exon45] - 
chr1:158612244 1 1.92 25 A/T SPTA1 rs202217097 deleterious(0)/probably_damaging(1) Leu1565Gln  [exon33] T:0.0032 
chr1:158612618 1 1.92 25 C/G SPTA1 rs143779235 tolerated(1)/benign(0) Ala1531Pro [exon32] G:0.0032 
chr8:41557033 4 0.097 12 C/T ANK1 rs34523608 tolerated(0.73)/benign(0.001) Arg832Gln [exon23] T:0.020 
chr1:158592847 22 0.051 11 G/A SPTA1 rs78394850 
deleterious(0)/probably_damaging(0.965
) Arg2016Cys  [exon43] A:0.14 
chr1:158592901 22 0.051 11 C/G SPTA1 rs77877855 
deleterious(0.01)/possibly_damaging(0.8
82) Ala1998Pro  [exon43] G:0.15 
chr8:41566438 4 0.20 13 C/T ANK1 rs2304877 deleterious(0.01)/benign(0.012) Arg619His [exon17] T:0.054 
chr8:41552213 4 0.21 13.5 G/A ANK1 rs35213384 tolerated(0.12)/benign(0.01) Thr1075Ile  [exon28] A:0.050 
chr17:42338993 1 -1.70 2 C/T SLC4A1 rs45562031 tolerated(0.45)/benign(0.173) Glu40Lys  [exon4] 
T:0.0028, 
T:0.0028 
chr17:42335888 1 -0.87 0 G/C SLC4A1 rs28931583 
tolerated(0.14)/possibly_damaging(0.549
) Pro327Arg [exon10] C:0.0023 
chr4:88989102 1 -0.091 12 G/A PKD2 rs145343957 
tolerated(0.09)/probably_damaging(0.93
4) Ser804Asn [exon13] A:0.0080 
chr17:42328598 8 -0.018 7.25 C/T SLC4A1 rs5026 tolerated(0.48)/benign(0.014) Val862Ile [exon19] T:0.10 
chr17:42334822 1 0.09 10 C/T SLC4A1 rs45568837 deleterious(0)/probably_damaging(1) Glu508Lys [exon13] T:0.0048 
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5. Discussion 
5.1 Aims 
 
The scope of this thesis was to provide empirical evidence of the genetic determinants of 
DRBC. The objectives were to identify common variants of small-to-moderate effect, in 
addition to rare variants with moderate-to-large effect associated with DRBC. Identifying the 
genetic modulator of DRBC could help identify erythrocyte channels and other pathway that 
could be targeted for therapies in SCD.  
We conducted a genome wide association study of 374 patients testing ~31 million imputed 
markers for association with DRBC. We prioritized variants looking at erythrocytes specific 
enhancers, and eQTLs for candidate genes involved in erythrocyte osmotic regulation. Plus, we 
sought to exploit the correlation between DRBC and MCHC, by retrieving variations in the 
largest GWAS of blood traits in non-anemic individuals. Additionally, we sequenced the 
exomes of a subset of individuals with extreme DRBC values looking for a relationship 
between genes involved with moving solutes and water across erythrocytes membrane to 
DRBC, and then to SCD-related complications. Contrary to the GWAS analysis, the aim was to 
find rare coding variants that could explain that increased levels of DRBC lead to increase 
severity of SCD.  
 
5.2 Significance of results 
 
Single-variants association tests, and gene-based tests did not yield any markers that reached 
genome-wide association threshold. Our prioritization strategy highlighted ATP2B4 the main 
calcium pump in erythrocytes, but functional experiments did not provide conclusive results for 
the role of plasma membrane calcium pump in SCD severity. Our WES experiment suggests 
that there is a direct relationship between DRBC and SCD. Indeed, we found rare DNA 
sequences mutations in ATP1B2, PIEZO1, SPTA1 and SLC12A7 in patients with multiple acute 
complications. Also, we found carriers of well characterized hereditary spherocytosis mutations 
in ANK1 and SLC41A. This indicates the presence of a concomitance of spherocytosis and 
sickle cell in our cohort, which is a rare but previously reported event. Amongst our total 
sample size other individuals with more extreme DRBC values are present. Validating the 
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exome sequencing approach by adding more samples at both end of the distribution tails would 
cement our findings and potentially open the door for the identification of specific pathways or 
transporters that can be targeted for therapies. Generally, our research findings suggest that 
DRBC should be more often recorded in routine blood test in SCD patients the same way 
MCV, MCH, and RETIC are. Systematically measuring DRBC in patients might be a better 
biomarker and indicator of severity than any other ones mentioned in the context of SCD. 
Clinical trials targeting transporter channels like the Gardos channel for Senicapoc (ICA-
17043) showed that modulating erythrocytes volume might be the most cost-effective and 
reliable approach to a cure for the vast majority of SCD individuals. 
 
5.3 Strength and limitations 
 
Our scientific inquiry has two major strength; first we are pioneering the genetic investigation 
on the density of red blood cell in SCD. Therefore, our work can aid future discoveries or 
clinical trials to guide their efforts away from negative results or towards new exciting 
questions. Our second strength is the consistency of our analysis pipelines. I developed 
automated routines for the prioritizations of the variants, and the visualization of summary 
statistics. Therefore making this work easily reproducible, and verifiable by others.  
In terms of limitations, the first one is our small sample size. This greatly limits our ability to 
replicate our current findings, which are essential for validating our results. The fact that 
DRBC is rarely recorded during full blood work exacerbates the challenge of performing a 
replication. The second limitation is our need for statistical power to identify common and rare 
variants with small effect size. In fact, according Zuk et al211, well-powered GWAS discovery 
sample sizes for common and rare variants associations test should have at least 25,000 cases 
with equally large replication sample size. This recommendation for half of 100,000 samples 
for both discovery and replication is more plausible today by joining large consortium such as 
the one on height, or obesity than it was 10 years ago. However, in the context of SCD, to date 
the largest GWAS analyzed fetal hemoglobin116 and was composed of less than 2,000 
individuals.  
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5.4 Recommendations 
 
Based on the limitations mention earlier, the most straightforward recommendation is to 
increase our sample size. As our power calculation showed, adding enough patients to reach a 
sample size of 1,000 would significantly improve our ability to find loci attributable to DRBC. 
Therefore, providing empirical candidate genes for functional experiments to reverse 
dehydration or rehydrate cells in animal models and eventually clinical trials. Another 
recommendation that could complement our grasp SCD severity and DRBC would be to 
acquire red blood cell metabolism data. This would capture small molecule reactions that are 
potentially associated with DRBC. In fact, metabolomics experiments have shown promising 
results in other complex traits disorders such as obesity and type-2 diabetes. In our context, we 
could seek to capture metabolomics signature of erythrocyte density or of volume control to 
fine tune our understanding of red blood osmotic regulation as it pertains to SCD, with 
implications to other blood disorders.  
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